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1. INTRODUCTION 
Development of a formulation involves a great deal of study and experimental 
work to get optimum results. While doing so we have to keep in mind various factors like 
choice of excipients, drug bioavailability, drug stability in required dosage form, cost 
effectiveness, manufacturing aspects, the patients‟ compliance and convenience. 
Nowadays formulation research is breaking barriers of conventional methods. 
Today, active ingredients can be delivered with a level of convenience, performance and 
bioavailability. 
First pass metabolism can be overcome by sublingual drug delivery and quick drug 
delivery into the systemic circulation can be obtained. Sublingual administration can offer 
an attractive alternative route of administration. The advantage of the sublingual drug 
delivery is that the drug can be directly absorbed into systemic circulation bypassing 
enzyme degradation in the gut and liver. These formulations are particularly beneficial to 
pediatric and geriatric patients. In addition, sublingual mucosa and abundance of blood 
supply at the sublingual region allow excellent drug penetration to achieve high plasma 
drug concentration with rapid onset of an action.
 1, 2
 
 
1.1 Oral Mucosa 
Oral mucosal drug delivery is an alternative method of systemic drug delivery and 
offers several advantages over both injectable and enteral methods. Because the oral 
mucosa is highly vascularized, drugs that are absorbed through the oral mucosa directly 
enter the systemic circulation, bypassing the gastrointestinal tract and first-pass 
metabolism in the liver. For some drugs, this results in rapid onset of action via a more 
comfortable and convenient delivery route than the intravenous route. Not all drugs, 
however, can be administered through the oral mucosa because of the characteristics of the 
oral mucosa and the physicochemical properties of the drug.
 3
 
The mucosal lining of the oral cavity are readily accessible, robust and heal rapidly 
after local stress or damage. Oral mucosal drug delivery systems can be localized easily 
and are well accepted by patients. Therefore, it is evident that the oral cavity can serve as a 
site for systemic drug delivery. The total surface area of the oral cavity is about 100 cm. 
The mucosal membrane of the oral cavity can be divided into five regions: the floor of the 
mouth (sublingual), the buccal mucosa (cheeks), the gums (gingiva), the palatal mucosa 
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and the lining of the lips. These oral mucosal regions are different from each other in 
terms of anatomy, permeability to drug and their ability to retain a system for a desired 
length of time. The buccal mucosa is less permeable than the sublingual mucosa. 
4
  In 
addition, the sublingual route has general advantages over other delivery routes, such as 
nasal, pulmonary, oral and transdermal systems. 
Advantages 
• Rapid onset of effect - particularly good for pain, emesis, insomnia or allergy 
relief  
 
• Easy, painless, discrete and convenient self-administration  
 
• Virtually all of drug absorbed across mucosa, none swallowed  
 
• Avoids first pass liver metabolism  
 
• Less variability in therapeutic effect, more predictable pharmacokinetics  
 
• Optimal effect achieved with less drugs, less side effects  
 
• No need for water, easy for patients who have difficulty in swallowing  
 
• Inexpensive to manufacture per dose  
 
• Flexible formulation options  
 
• No irritation or damage to tissues  
 
• For drugs which are unstable in gastric pH  
 
• The blood supply is rich with a capillary network close to mucosa  
 
Within the oral mucosal cavity, delivery of drugs is classified into three categories, 
1. Sublingual delivery: This is systemic delivery of drugs through the mucosal 
membranes lining the floor of the mouth.
5
 
2. Buccal delivery: This is the drug administration through the mucosal membranes 
lining the cheeks (buccal mucosa).
6
  
3. Local delivery: This is drug delivery into the oral cavity.7  
 
1.1.1. Sublingual absorption 
Sublingual literally meaning “Under the Tongue”, refers to a method of 
administering substances via the mouth in such a way that the substances are rapidly 
absorbed via the blood vessels under the tongue rather than via the digestive tract. The 
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route of absorption via the highly vascularized buccal mucosa allow the substance a more 
direct access to the blood circulation, thus providing direct systemic administration. 
Medically, sublingual drug administration is applied in the field of cardiovascular 
drugs, steroids, some barbiturates and enzymes. It has been a developing field in the 
administration of many vitamins and minerals which are found to be readily and 
thoroughly absorbed by this method.
 8, 9
 
There is considerable evidence that most sublingual substances are absorbed by 
simple diffusion; the sublingual areas acting rather like litmus paper, readily soaking up 
the substance. However, not all substances are permeable and accessible to the buccal 
mucosa. The mucosa functions primarily as a barrier-similar to skin. It was once believed 
that the barrier of human skin was „impenetrable‟ (e.g., Vitamins E and C creams, 
hormones, nicotine patches) but still it is a growing field of endeavor. Similarly the buccal 
mucosa presents an ideal site for absorption. 
One of the best known drugs used regularly with great success is glyceryl trinitrate 
a potent coronary vasodilator which is used for the rapid symptomatic relief of angina. It 
has been found impressively effective and when administered sublingually; 
pharmacologically active after only 1-2 minutes. The administration via an aerosol spray 
was found to provide rapid relief of symptoms, with first-pass metabolism. The extent of 
first-pass metabolism when compared to the sublingual spray decreased to 48% with 
sublingual tablets and 28% with oral dose.
10 
 Following sublingual administration, nitrates appears in plasma, concentration can 
be maintained for 24 hrs. Sublingual verapamil ( a calcium channel blocker prescribed for 
the management of angina, hypertension and  certain supraventricular arrhythmias) was 
effective in controlling the ventricular rate in patients symptomatically  and rapidly 
appeared in the plasma following sublingual administration.
11
 Experiments with some 
analgesics showed  many times more rapid absorption from the mouth than the less lipid 
soluble morphine. Impressive absorption has been attained with sublingual administration 
of desoxycortisone acetate, morphine, captopril, nifedepine and 17-β oestradiol 
interestingly; it has also been shown that the sublingual administration of 17-β Oestradiol 
requires only one fourth of the oral dose.
 12, 13, 14 
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Figure: 1.1. Diagram of Sublingual Gland and Sublingual Artery 
 
1.1.2 The mechanism of Sublingual absorption 
8, 9
 
The absorption potential of the buccal or sublingual mucosa is influenced by the 
lipid solubility and therefore the permeability of the solution (osmosis), the ionization 
(pH) and the molecular weight of the substances. For example, absorption of some drugs 
via buccal or sublingual mucosa epithelium. It is also unlikely that active transport 
processes operate within the oral mucosa. However, it is believed that acidic stimulation 
and uptake into the circulatory system occurs. 
The mouth is lined with mucous membrane which is covered with squamous 
epithelium and contains mucous glands. The buccal mucosa is similar to the sublingual 
mucosal tissue. 
The salivary glands consist of lobules of cells which secrete saliva through the 
salivary ducts into the mouth. The three pairs of salivary glands are the parotid, the 
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submandibular and the sublingual which lies on the floor of the mouth.  The more acid the  
taste, the  greater  the   stimulation  of  salivary  output,  serving  also  to  avoid  potential 
harm to  acid sensitive tooth enamel by bathing the mouth in copious neutralizing fluid. 
With stimulation of salivary secretion, oxygen is consumed and vasodilator substances are 
produced and the glandular blood flow increases, due to increased glandular metabolism. 
The sublingual artery travels forward to the sublingual gland, it supplies the gland 
and branches to the neighbouring muscles and to the mucous membranes of the mouth, 
tongue and gums. Two symmetrical branches travel behind the jaw bone under the tongue 
to meet and join at its tip. Another branch meets and anastomoses with the sub mental 
branches of the facial artery. The sublingual artery system stems from the lingual artery – 
the body‟s main blood supply to the tongue and the floor of the mouth – which arises from 
the external carotid artery. The proximity with the internal carotid artery allows fast access 
to its route supplying the greater part of the cerebral hemisphere. 
 
1.1.3 Osmosis 
8, 15
 
In order for a nutrient to be effectively absorbed sublingually, it needs to be able to 
travel across the buccal mucosa membranes by a process of diffusion known as osmosis 
which applies to all forms of absorption by the body, governing both intestinal and 
sublingual absorption. The distribution of water across the cell walls depends on the 
osmotic difference in the blood, between the intracellular and extracellular fluid. The 
distribution of water across the blood vessel walls is determined by the in-vivo osmotic 
pressure of plasma and the total outward hydrostatic pressure. Unlike the cell membrane, 
the capillary wall is freely and rapidly permeable to small molecules.  
  The diffusion of water  across  a  membrane  that  is  only  permeable  to water  
depends  on  the  molecular weight  of  the  particle.  Small  particles  that readily  
dissolve  in  water,  rarely  present  a problem in permeation and diffusion, and so are able 
to move freely between the tissues of  the  body.  Active transportation into cells leads to 
rapid metabolism of the substances. Molecules such as glucose (fructose) and amino acids 
are essential for cell metabolism and special mechanisms have evolved to facilitate their 
rapid diffusion and permeation across cell membranes. 
 
1.1.4 Structure of Oral Mucosa 
16
 
In general terms, the oral mucosa is made up of an outermost layer of stratified 
squamous epithelium, which is covered with the mucous and consists of stratum 
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distendum, stratum filamentosum, stratum suprabasale and a stratum basale. Below these 
lie a basal lamina, the lamina propria and the sub mucosa. The epithelium serves as the 
mechanical barrier that protects underlying tissues, whereas the lamina propria acts as a 
mechanical support and also carries the blood vessels and nerves. Some regions of the oral 
mucosa are keratinized, whereas others are not. The non-keratinized regions, such as 
buccal and sublingual are more permeable than the keratinized regions. This is due to 
some extent, to the composition of intracellular lipids comprising the particular region. 
Whereas keratinized regions contain predominantly neutral lipids (ceramides). Non- 
keratinized areas are composed of glycosyl ceramides that appears to be derived from 
membrane coating granules that differ morphologically from the lamellate membrane-
coating granules of keratinized tissue. 
In general it appears that the patterns of epithelial differentiation in the oral 
mucosa vary to produce a surface layer that sufficiently meets the demands placed upon 
that particular tissue. Furthermore, in dealing with drug delivery, the amount of a certain 
drug absorbed through the oral mucosa is determined by many factors, including the pKa 
of  the  base,  the  rate  of  partition  of  the  unionized  form of  the  drug,  the  lipid–water 
partition coefficient of that particular drug, and lastly, on the pH of the solution. 
 
Figure 1.2. Structure of the oral mucosa 
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1.2. Sublingual Dosage Forms 
These dosage forms are designed to deliver the drugs in the vicinity of sublingual 
mucosa. Drugs administered by this route produce systemic/local effects. In general, rapid 
absorption form this route is observed because of the thin mucous membrane and rich 
blood supply. 
 
The sublingual dosage forms can be classified into the following: 
 
• Sublingual Tablets  
 
• Sublingual Spray  
 
• Sublingual Capsules  
 
• Sublingual Films 
 
1.2.1. Sublingual Tablets
 17 
             Sublingual tablets are intended to be placed beneath the tongue and held until 
absorption has taken place. They must dissolve or disintegrate quickly, allowing the 
medicament to be rapidly absorbed. 
1.2.2 Sublingual Spray 
18
 
Sublingual sprays are the dosage forms in which the drug is dissolved or dispersed 
in a vehicle and filled in vials with metered value. On actuation, a desired dose of the drug 
will deliver through the valve. 
1.2.3. Sublingual Capsules 
18
 
These are the solid dosage forms in which the powder is filled into capsule, it 
should be cut open and the contents are poured below the tongue. 
e. g. Nifedepine sublingual capsule. 
1.2.4. Sublingual Films 
19
 
These are thin, transparent films, which are kept under the tongue form which drug 
will reach and get absorbed into blood stream. e. g. diazepam 
 
1.3. Formulation of Sublingual Tablets 
The distinct feature in the formulation of sublingual tablets involves the selection 
of suitable excipients of bland taste that shall ultimately result in a rapid disintegrating 
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tablet there by enhancing the dissolution of active ingredient. 
There are two different types of sublingual tablets: 
A. Molded Sublingual Tablets  
 
B. Compressed Sublingual Tablets  
 
1.3.1. Molded Sublingual Tablets 
20
 
             Molded sublingual tablets are usually prepared from soluble ingredients so that the 
tablets are completely and rapidly soluble.  They contain, in addition to drug, excipients or 
base namely lactose, dextrose, sucrose, mannitol, or other rapidly soluble materials or 
mixtures of these ingredients.       
This tablet shows the same bioavailability as conventional tablets but has the 
advantage of markedly improved stability. In contrast to conventional tablets, which often 
develop marked inter tablet dose variation within 1 month, the stabilized tablet maintains 
its content uniformity for long periods, even at 37 ºC and 45 ºC, thus assuring a more 
uniform and predictable dose to the patient. 
 
1.3.2. Compressed Sublingual Tablets 
21
 
The requirements for sublingual tablets are speed of absorption and a 
correspondingly rapid physiological response, which are normally best achieved with a 
rapidly soluble molded tablet. Compressed sublingual tablets can be prepared by two 
different methods: 
 
a) Wet Granulation Method  
 
b) Direct Compression Method.  
 
 
1.3.2.1.Wet Granulation Method  
The wet granulation method of the tablet production is essentially a process of size 
enlargement, sticking particles of the drug and excipients together using an adhesive, to 
produce a granular product with improved flow properties and an increased ability to 
cohere under pressure. 
The drug and excipients are passed through particular sieve, and are mixed 
together to get uniform mixture. Suitable granulating agents like water, starch paste, 
povidone are added to the powder mixture in the appropriate proportion to produce a 
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coherent mass. This mass is  passed through a suitable sieve  and dried  at optimum  
temperature  and  sieved  to  get  uniform  granules. Then the granules are lubricated and 
compressed into a tablet.   
 
1.3.2.1. Direct Compression Method  
Direct compression is the easiest way to manufacture tablets and also fast melting 
tablets. The  term  direct  compression  is  used  to  define  a  process  by  which   tablets  
are compressed directly from the powder blends of active ingredients  and suitable 
excipients, which  will  flow uniformly  into  the  die  cavity  and  form  into  a  firm  
compact.  The great advantage of direct compression is the manufacturing cost. It uses 
conventional equipment, commonly available excipients and a limited number of process 
steps. 
 
1.4. Major mechanisms by which tablet disintegrate in mouth 
22
  
1.4.1 Swelling by Disintegrants 
Although not all effective disintegrants swell in contact with water, swelling is 
believed to be a mechanism by which certain disintegrants impart their disintegrating 
effect. By swelling in contact with water, the adhesiveness of other ingredients in a tablet 
is overcome causing the tablet to fall apart. Swelling could be of following types, 
 
 Swelling extensively in all dimensions 

 Recover shape with little swelling 

 Swell readily and strengthen out as seen in the case of fibrous material 

1.4.2 Porosity and Capillary Action (Wicking) 
Effective disintegrating action is available through porosity and capillary action. 
Tablet porosity provides pathways for the penetration of fluid into the tablets. The 
Disintegrate particles (with low cohesiveness and compressibility) themselves act to 
enhance porosity and provide these pathways into the tablet. Liquid is drawn up or 
„wicked‟ into these pathways through capillary action and rupture the inter-particulate 
bonds causing the tablet to break apart. 
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1.4.3 Deformation 
               Starch grains are generally thought to be “elastic” in nature meaning that the 
grains that are deformed under pressure will return to their original shape when that 
pressure is removed. But with the compression forces involved with tabulating, these 
grains are believed to be deformed more permanently and are said to be “energy rich” 
with this energy being released upon exposure to water. In other words, the ability of 
starch to swell is higher in “energy rich” starch grains than it is for starch grains that have 
not been deformed under pressure. 
It is believed that no single mechanism is responsible for the action of most 
disintegrants. But rather, it is more likely the result of interrelationship between these 
major mechanisms. 
 
1.5. General Technology 
23
 
 
• Freeze Drying 
 
• Tablet Molding 
 
 
1.5.1 Freeze Drying 
Freeze drying is also commonly known as lyophilization process in which water is 
sublimated from the product after freezing. The ideal drug characteristics for this process 
are relative water insolubility with fine particle size and good aqueous stability in 
suspension. Primary problems associated with water soluble drugs are formation of 
eutectic mixture resulting in freezing point depression and formation of glassy solid on 
freezing, which might collapse during sublimation. Therefore additions of cryoprotectants 
like crystal forming agents induce crystallinity and impart rigidity to amorphous solid. 
This technique allows drying of heat sensitive drugs and biologicals at low 
temperature thereby eliminating adverse thermal effects and can be stored in dry state with 
relatively new shelf life. Freeze dried forms offer more rapid dissolution time than other 
solid products because this technique offers highly porous powder with a very high 
specific surface area. 
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1.5.2 Tablet Molding 
In this method, tablets are produced by molding of solid dispersion usually 
consisting of water soluble additives, drug and other excipients. Initially the dry blend of 
all the ingredients is wetted with a hydro alcoholic solvent and then compressed into 
tablets using low compression forces. Porous tablets are formed as the solvent present 
inside the tablet is removed by air drying. 
Different mold techniques employed are 
• Compression molding : Here the powdered mixture previously moistened with a 
solvent like ethanol/water is compressed into moulds plate to form a wetted mass  
• Heat molding : The molded forms can be obtained from a molten matrix in which 
the drug is dispersed  
• No vacuum lyophilization: In this process, at standard pressure the solvent from 
the drug solution or suspension is evaporated 
 
1.6. Other Techniques 
24
 
1.6.1. Sublimation 
Compressed tablets composed of water soluble excipients as tablet matrix often 
does not disintegrate due to low porosity. Therefore to increase the porosity of tablet an 
inert solid ingredient that volatilizes readily, example camphor, ammonium bicarbonate, 
naphthalene, urea etc. are mixed with other ingredients and then the mixture is compressed 
into tablets. The volatile material is removed via sublimation, which generates porous 
structure. 
1.6.2. Spray Drying 
Spray drying technique produces highly porous and fine powders as the 
processing solvent is evaporated during the process. This technique provides tablets that 
show fast disintegration and enhanced dissolution. Allen, Wang et al reported a spray 
drying technique using hydrolyzed and non-hydrolyzed gelatin as a support matrix, 
mannitol as a bulking agent, sodium starch glycolate as disintegrant, an acidic material 
like citric acid and/or alkaline material i.e. sodium bicarbonate. The tablets made from 
this technology are claimed to disintegrate within 20 seconds. 
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Table 1.1. Some Marketed Sublingual Tablets 
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Brand name  Drug Category Strength 
Abstral Fentanyl citrate Opioid analgesics 50,100,200,300,400,600 and 
800 mcg 
Subutex Buprenorphine  Opioid analgesics 2 and 8 mg 
Avitan Lorazepam Antianxiety 1 and 2 mg 
Edular Zolpidem tartrate Sedative/ hypnotics 5 and 10 mg 
Isordil Isosorbide dinitrate  Vasodilators 2.5,5 and 10 mg 
Suboxone Buprenorphine HCl + 
naloxone 
Narcotic + Opioid 
analgesics 
2/0.5, 8/ 2 mg 
Saphris Asenapine Antipsychotic agent 5 and 10 mg 
Prohealth 
melatonin 
Melatonin Hormone 2 mg 
Nitrostat Nitroglycerine Antianginal 0.3, 0.4 and 0.6 mg 
Temegesic Buprenorphine Opioid analgesics 200mcg 
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Amarjit P. Rajput (2013) et al.
 26
 (2013) reported comparative study of various 
permeation enhancers for development of sumatriptan succinate buccal tablet. The  aim  of  
the  present  study  was to  prepare  buccoadhesive  sustained  release  tablets  of 
sumatriptan succinate using various permeation enhancers to release the drug for extended 
period of time with reduction in dosing frequency. Fulvic acid was characterized by 
various spectroscopic techniques. Buccoadhesive  sustained  release  tablets  of  
sumatriptan  succinate  with  various  permeation enhancers  were  prepared  by  direct  
compression  method  using  bioadhesive  polymers  like Carbopol 934 and HPMC 
K100M. The physical characteristics like surface pH, swelling index, in vitro 
mucoadhesion time, in vitro mucoadhesion strength, in vitro drug release study and in 
vitro permeation study were studied.  The in vitro release study showed 99.88%, 99% and 
99.40% of drug release with fulvic acid, chitosan and beta cyclodextrin respectively. The 
permeation study showed 90%, 82%  and  78%  of  drug  permeated  with  fulvic  acid,  
chitosan  and  beta  cyclodextrin  respectively. Sumatriptan succinate release from the 
buccoadhesive system was extended and exhibited a non fickian  drug  release  kinetics  
approaching  to  first  order  as  the  values  of  release  rate  exponent varied between 0. 97 
to 0.99 resulting in a regulated and complete release until 8 hours.   
Balusu Haarika et al. 
27
 (2012) reported formulation and evaluation of fast disintegrating 
rizatriptan benzoate sublingual tablets. Sublingual formulation has the advantage of 
offering fast relief from migraine due to faster drug delivery. The present study involves 
the formulation and evaluation of fast  disintegrating  sublingual  tablets  of  rizatriptan  
benzoate  to  produce  intended  effects.  The sublingual  rizatriptan  benzoate  tablets  
were  prepared  by  the  method  of  direct  compression.  The superdisintegrants used 
were sodium starch glycolate, cross carmellose sodium and cross povidone. The  powder  
flow  properties  of  all  formulations  were  evaluated  for  diameter,  thickness,  weight 
variation,  hardness, friability,  wetting  time,  water  absorption  ratio,  drug  content,  in 
vitro  and  in vivo disintegration time as well as in vitro release and were found to be 
satisfactory. The optimised formulation  containing  cross  povidone  disintegrated  very  
fast  and  in vitro  drug  release  was  very high.  Based  on  disintegration  and  dissolution  
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studies,  the  optimised formulation  was  also  evaluated  for  in vivo  release  studies  
using  rabbit  model.  
Rameshwari S et al. 
28
 (2009) studied the sublingual tablets of nifedipine. Nifedipine 
sublingual tablets were prepared by direct compression method. Three different groups of 
formulation with variation of tablet excipients were prepared with each group containing 
five different formulations. Various excipients were used in the formulation like Avicel 
pH 101, mannitol, lactose, magnesium stearate, talc, sodium saccharin, aerosol, citric acid, 
SSG, croscarmelose sodium etc. All batches of the tablets were preliminarily evaluated for 
various physical parameters such as hardness, friability drug content, disintegration and 
dissolution. This study clearly indicated the fast disintegration and dissolution of the 
optimized nifedipine sublingual tablet, which is a prerequisite for the rapid management 
of anginal hypertension diseases. 
 
Abraham S et al. 
29
 (2010) studied the sublingual tablets of rabeprazole sodium. Various 
excipients were used in the formulation like crospovidone, croscarmelose sodium, 
mannitol, mango flavor, aspartame, talc, lactose etc. 10 batches of tablets were prepared 
using Central composite design. In this study, the amount of Crospovidone and CCS were 
chosen as the independent formulation variables, and the dependent variables included 
wetting time and in vitro dispersion time. The effect of formulation variables on the 
response variables were statically evaluated by applying one-way ANOVA at 0.05 level 
using Design-Expert®. They gave optimized formula of sublingual tablet of rabeprazole. 
 
Bolourchian N et al. 
30
 (2009) reported sublingual tablets of physostigmine salicylate. 
The active ingredient was physostigmine salicylate. The other materials were as follows: 
polyvinyl pyrrolidone (PVP K10) and ammonium acetate, starch 1500, sodium starch 
glycolate, lactose, magnesium stearate and acetonitrile HPLC grade. Various parameters 
were evaluated like hardness, friability, disintegration, drug release etc. Increasing the 
percentage of PVP or starch 1500 and decreasing the amount of lactose in tablet 
formulation showed higher hardness value. This was predictable, because both PVP and 
starch 1500 have a binding effect in tablet formulation. For instance, an increase in starch 
1500 concentration in tablets from 10 to 12 %, with the same amount of PVP, modified 
tablet hardness. 
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Bolourtchian N et al. 
31
 (2008) developed and optimized sublingual tablet formulation of 
Captopril which is an effective drug in the treatment of hypertension. Captopril containing 
tablets were prepared by direct compression method using different ingredients such as 
polyvinyl pyrrolidone, starch 1500, sodium starch glycolate and lactose (independent 
variables) and magnesium stearate, talc and aspartame (fixed components). Tablets were 
evaluated for the physical properties including hardness, disintegration time and friability 
which were considered as responses in a D-optimal experimental plan. Results were 
statistically examined using special cubic model and polynomial mathematical equations 
and found to be statistically significant (p< 0.05) for disintegration time and friability data. 
The physical data from the numerical optimization were verified and found to be very 
close to those predicted from the regression analysis. Additional experiments including 
drug content, in vitro drug dissolution rate and accelerated stability studies were also 
performed on the optimum formulation. All results were in accordance with the 
requirements of a sublingual tablet. 
 
Sharma R et al. 
32
 (2010) Studied fast disintegrating sublingual tablets of glipizide. They 
used Glipizide, Crospovidone, Sodium starch glycolate & Lactose-IP, polyvinyl 
pyrrolidine and colloidal silicon dioxide, Magnesium stearate, naphthalene for formulation 
of glipizide sublingual tablet. For the preparation of tablets, vacuum drying technique was 
used and water insoluble diluents such as microcrystalline cellulose and dicalcium 
phosphate were not used in this study because they can be expected to cause an 
unacceptable feeling of grittiness in the patient mouth. These tablets were evaluated for 
weight variation test, hardness, friability, water absorption ratio, disintegration time and 
in-vitro dissolution rate. Naphthalene was used as sublimation agent. In this research work 
it was found that the amount of naphthalene and crospovidone considerably affect the 
various parameters such as wetting time, disintegration time, and percentage friability. It is 
thus concluded that by adopting a systematic formulation approach, an optimum point can 
be reached in the shortest time with minimum efforts. 
 
Shirsand SB et al. 
33
 (2010) studied fast dissolving tablets of Metoclopramide 
hydrochloride. They used crosscarmelose, crospovidone, pearlitol SD 200 etc. Fast 
dissolving tablets of metoclopramide hydrochloride were prepared using the above co-
processed superdisintegrants and evaluated for pre-compression and post-compression 
parameters. Directly compressible mannitol (Pearlitol SD 200) was used as a diluent to 
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enhance mouth feel. Co-processed superdisintegrants consisting of crospovidone and 
croscarmellose sodium exhibited good flow and compression characteristics. MTH tablets 
containing co-processed superdisintegrants exhibited quick disintegration and improved 
drug dissolution. 
 
Bhanja SB et al. 
34
 (2011) studied sublingual tablets of Perindopril. The objective of the 
current study was to develop and optimize sublingual tablet of Perindopril which is an 
effective drug in the treatment of hypertension. Perindopril containing tablets were 
prepared by direct compression method using different ingredients such as crospovidone, 
sodium saccharin, mannitol, microcrystalline cellulose and magnesium stearate. The 
tablets were evaluated for physical properties including hardness, weight variation, 
thickness, friability, drug content, wetting time, water absorption ratio, in-vitro 
disintegration time, in-vitro dissolution study and drug release kinetic study. They found 
that formulation has high disintegration time because of presence of crospovidone. 
 
Avulapati S et al. 
35
 (2011) Studied on fast disintegrating tablets of Losartan Potassium. 
The basic approach followed in this study was to incorporate a combination of 
superdisintegrants in optimum concentrations which can minimize disintegration time. 
The various superdisintegrants used in the present study were croscarmellose sodium, 
crospovidone and sodium starch glycolate. Various batches of FDTS were prepared by 
direct compression method and using conventional tablet machine. The formulated FDTS 
were evaluated for various physicochemical parameters, disintegration time and for in 
vitro drug release. All the batches of the formulations possessed required physicochemical 
parameters. The disintegration time of various formulations ranged from 16 to 51 seconds. 
In vitro drug release for various formulations ranges from 95.23 to 99.90 % end of 5 
minutes. 
 
Bhardwaj V et al. 
36
 (2010) prepared sublingual tablets of Amlodipine besylate. The aim 
of this study was to prepare fast disintegrating tablets of Amlodipine besylate by using 
different disintegrants and to evaluate the effect of increasing Amlodipine besylate load on 
the characteristics of fast disintegrating sublingual tablets for the potential emergency 
treatment of angina and hypertension. The superdisintegrant used in this study were 
Kollidon CL, Ac Di Sol and Sodium Starch Glycolate in varying concentrations (2 %, 4 
%, and 6 %). The tablets were evaluated for weight variation, hardness, friability, wetting 
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time, water absorption ratio, and disintegration time and dissolution study. Using the same 
excipients, the tablets were prepared by direct compression and were evaluated in the 
similar way. From the results obtained, it can be concluded that the tablet formulation 
prepared with Ac Di Sol showed average disintegration time of 16 seconds in vitro that is 
faster than the other superdisintegrants used in the study. Also the hardness, friability, 
dissolution rate and assay of prepared tablets were found to be acceptable according to 
standard limits. The stability studies were performed as per ICH guidelines. 
 
Nagendrakumar D et al. 
37
 (2010) prepared fast dissolving tablets of Granisetron. In the 
present work, fast dissolving tablets of Granisetron HCl were prepared using novel co-
processed superdisintegrants consisting of crospovidone and sodium starchglycolate in 
different ratios (1:1, 1:2 & 1:3). The developed superdisintegrants were evaluated for 
angle of repose, Carr’s index and Hausner’s ratio in comparison with physical mixture of 
superdisintegrants. Fast dissolving tablets of Granisetron hydrochloride were prepared 
using the above co-processed superdisintegrants and evaluated for precompression and 
post-compression parameters. Based on in vitro dispersion time (approximately 20 sec), 
promising formulation was tested for in vitro drug release pattern in pH 6.8 Phosphate 
buffer and short-term stability (at 400
o
C/75 % RH for 3 months) and drug excipients 
interaction (IR spectroscopy) were studied. Among the designed formulations, the 
formulation containing      4% w/w of co-processed superdisintegrant (1:1 mixture of 
crospovidone and sodium starchglycolate) emerged as the overall best formulation (t50 % 
2.0 min) based on drug release characteristics in pH 6.8 phosphate buffer compared to 
commercial conventional tablet formulation (t50 % >15 min). 
 
Jangam V et al. 
38
 (2011) studied orodispersible tablets of Carvedilol. The present study 
was aimed towards the formulation and evaluation of orodispersible tablets by direct 
compression technology using Carvedilol as a model drug. Orodispersible tablet of 
Carvedilol was formulated using lactose in different concentration (10%, 20%, and 30%) 
of superdisintegrants like crospovidone and sodium starch glycolate and diluents. 
Disintegration time and drug release were taken as the basis to optimize the orodispersible 
tablet. All the Prepared tablets were evaluated for thickness, hardness, friability, 
uniformity of weight, disintegration time, and dissolution study. Crospovidone in the 
concentration of 15 % gives faster disintegration time in 16 sec. and shows 100 % drug 
release within 15 min. This formula was selected as optimized formulation. 
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Gokel Y et al. 
39
 (2001) prepared sublingual tablets of Valsartan. The objective of this 
study was to assess the effect of sublingual valsartan in a group of patients with 
hypertensive urgency. Forty-one patients with hypertensive urgency and systolic blood 
pressure >200 mmHg, diastolic blood pressure >100 mmHg were studied in an emergency 
room. Supine blood pressure readings were taken and the patients were given 80 mg of 
valsartan sublingually. Blood pressure and heart rate were recorded at 15 min intervals 
over a 90 min period. Systolic blood pressure decreased from 211.22 ± 14.65 mmHg to 
158.17 ± 15.48 mmHg, diastolic blood pressure dropped from 120.12 ± 13.44 mmHg to 
93.05 ± 6.01 mmHg. The differences were statistically significant. The heart rate 
decreased from 87.90 ± 13.47 beats per minute to 82.59 ± 10.84 beats per minute. The 
results of the study indicate that sublingual valsartan is an effective drug in patients with 
hypertensive urgency and it is easy to use sublingually because it is in a capsule form and 
it is side-effect free. Further work is required to assess the effect of sublingual valsartan in 
patients with hypertensive urgency. 
 
 
Bhowmik D et al. 
40
 (2009) studied on fast dissolving tablets of Telmisartan. Telmisartan 
is an Anti-hypertensive drug which is insoluble in water; hence the drug may be slowly or 
incompletely dissolves in the gastro-intestinal tract. So the rate of dissolution and therefore 
its bioavailability is less (bioavailability 42%). In the present study an attempt has been 
made to prepare fast dissolving tablets of Telmisartan by using superdisintegrants–
crosspovidone, ac-di-sol, and sodium starch glycolate, level of addition to increase the rate 
of drug release from dosage form to increase the dissolution rate and hence its 
bioavailability. The tablets were prepared by direct compression methods and the prepared 
blend and tablets were evaluated for their physicochemical properties and in-vitro 
dissolution study. The evaluation study was performed such as weight variation, thickness, 
hardness, disintegrating time, wetting time, and in-vitro drug release and stability study. 
The disintegration time of fast dissolving tablets were increased by the addition of 
concentration of superdisintegrants. 
 
Madan J et al. 
41
 (2009) studied fast dissolving tablets of Aloe Vera gel. The objective of 
this work was to prepare and evaluate fast dissolving tablets of the nutraceutical, freeze 
dried aloe vera gel. Fast dissolving tablets of the nutraceutical, freeze-dried aloe vera gel, 
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were prepared by dry granulation method. The tablets were evaluated for crushing 
strength, disintegration time, wetting time, friability, drug content and drug release. A 3
2
 
full factorial design was applied to investigate the combined effect of two formulation 
variables - amounts of microcrystalline cellulose and mannitol. The results of multiple 
regression analysis revealed that in order to obtain a fast dissolving tablet of the aloe vera 
gel, an optimum concentration of mannitol and a higher content of microcrystalline 
cellulose should be used. A response surface plot was also provided to graphically 
represent the effect of the independent variables on the disintegration time and wetting 
time. The validity of the generated mathematical model was tested by preparing a check 
point batch. This investigation has demonstrated that satisfactory fast dissolving Aloe 
Vera gel tablets can be formulated. It also showed the potential of experimental design in 
understanding the effect of formulation variables on the quality of fast dissolving tablets. 
 
Tayel SA et al. 
42
 (2010) prepared sublingual tablets, containing the anti-asthmatic drug 
Ketotifen fumarate which suffers an extensive first-pass effect, using the fast-melt 
granulation technique. The powder mixtures containing the drug were agglomerated using 
a blend of polyethylene glycol 400 and 6000 as meltable hydrophilic binders. Granular 
mannitol or granular mannitol/sucrose mixture were used as fillers. The melt granulation 
technique is a process by which pharmaceutical powders are efficiently agglomerated by 
the use of a low melting point binder which is added to the other components of the 
powder. Once in a molten state, the binder acts as a granulating liquid. Preparation can 
take place by melting the low melting point compound, then, the water soluble excipients 
are added. The combination is mixed until congealing takes place to make granules. The 
objective of this work was to prepare a sublingual tablet containing the Anti-asthmatic and 
Anti-allergic drug Ketotifen fumarate, so as to improve its bioavailability, which was only 
50 % following oral ingestion. 
 
 
Madhu SS et al. 
43
 (2006) evaluated the effect of polymer type and tablet compaction 
parameters on the adhesive properties and drug release profile from mucoadhesive 
sublingual tablet formulations. Pentoxifylline was selected as the model drug because it 
has poor oral bioavailability due to extensive first-pass metabolism. Two polymers known 
to possess mucoadhesive properties, carbomer and hydroxypropyl methyl cellulose 
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(HPMC), were used to prepare the formulations. For drugs prone to presystemic losses, 
one of the approaches to improve drug bioavailability could be the use of buccal, 
sublingual, or gingival routes of administration, which could effectively minimize losses 
due to first-pass metabolism, enzymatic degradation, and/or degradation attributable to 
low pH environments. In addition, these routes of administration could offer the advantage 
of rapid onset of drug action as the rich supply of blood vessels in the oral cavity 
immediately transports the drug substance to the systemic circulation. It has been reported 
that the sublingual route is more permeable than buccal or gingival routes and also 
provides superior bioavailability with faster and less erratic absorption for many drugs. 
 
Ravishankar et al. 
44
 (2011) studied sublingual Piroxicam in migraine. The aim of the 
present study was to compare the analgesic efficacy of a single dose of sublingual 
Piroxicam to that of a placebo during acute attacks of migraine without aura. The drug or a 
placebo was administered, on randomisation and double-blind basis, to 60 patients 
between 18 and 50 years of age suffering from migraine without aura. The patients were 
instructed to take a single tablet sublingually [corresponding to piroxicam 40mg or 
placebo] and the severity of the painful symptomatology and associated symptoms were 
evaluated by this study. The patients treated with sublingual piroxicam showed a 
significant decrease in pain intensity 15 min. after ingestion; they went on to show a 
further reduction in the 24 h after drug administration. On the contrary, the group treated 
with placebo showed a significant reduction of symptoms only after seven hours of 
observation. 
 
Bredenberg S et al. 
45
 (2003) introduced a new tablet system for sublingual 
administration and rapid drug absorption. The tablet is based on interactive mixtures of 
components, consisting of carrier particles partially covered by fine dry particles of the 
drug, in this case Fentanyl citrate. In the interests of increasing retention of the drug at the 
site of absorption in the oral cavity, a bioadhesive component was also added to the carrier 
particles. Tablets containing 100, 200 and 400 µg of fentanyl were tested both in vitro and 
in vivo. Plasma concentrations of fentanyl were obtained within 10 min, with no second 
peak. A rapid onset of pharmacological effect is often desired from drugs, especially in the 
treatment of acute disorders. This can effectively be achieved by parenteral administration, 
but this method may not always be convenient for the patient. Therefore, there is growing 
interest in developing new, non-parenteral, reliable and convenient dosage forms using 
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administration routes where a rapidly dissolved drug is immediately absorbed into the 
systemic circulation. Tablet formulations are generally the first choice for drug 
administration because of ease of both production and usage. 
 
Deveci S et al. 
46
 (2004) studied the effect of sublingual Sildenafil. Aim of the study was 
to show the efficacy and safety of sublingual Sildenafil with a faster onset of action in this 
mode of application. It was concluded that 20 mg sublingual Sildenafil is safe and 
effective in the treatment of erectile dysfunction. Sublingual administration has some 
advantages as it is not affected by food ingestion and quickly appears in the circulation. 
These advantages provide a faster onset of action with a lower dose when compared to 
oral Sildenafil. Sublingual use of Sildenafil may be more cost-effective and possibly 
provides a more predictable onset of action. 
 
 
Kulkarni SV et al. 
47
 (2010) prepared fast disintegrating tablets of Meloxicam that 
disintegrate in the oral cavity upon contact with saliva and thereby improve therapeutic 
efficacy. Meloxicam is newer selective COX-2 inhibitor. The tablets were prepared by wet 
granulation procedure. The influence of superdisintegrants like crosspovidone, 
croscaremellose sodium on disintegration time, wetting time and water absorption ratio 
were studied. Tablets were evaluated for weight and thickness variation, disintegration 
time, drug content, in vitro dissolution, wetting time and water absorption ratio. The in 
vitro disintegration time of the best fast disintegrating tablets was found to be 18 sec. 
Tablets containing crospovidone exhibit quick disintegration time than tablets containing 
croscaremellose sodium. The fast disintegrating tablets of Meloxicam with shorter 
disintegration time, acceptable taste and sufficient hardness could be prepared using 
crospovidone and other excipients at optimum concentration. 
 
Narendra C et al. 
48
 (2005) formulated a sublingual tablet formulation of Terbutaline for 
rapid action, and to improve both bioavailability and patient compliance to therapy. A wet 
granulation technique was adapted to prepare the granules. Granule formulations were 
prepared using an adapted wet granulation technique based on a 3
2 
full factorial design. 
Conventional dosage forms for the management of asthma include tablets, capsules, 
syrups, injections and metered dose inhalers. Meter dose inhalers provide effective rapid 
relief, but at the same time, they present the disadvantage of requiring sophisticated 
equipment to manufacture, may be harmful to the environment and are expensive. In this 
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study, an attempt has been made to formulate sublingual dosage formulations of 
Terbutaline by using experimental design technique. 
 
R.V.Kenny et al 
49 
(2010) studied formulation and evaluation of rizatriptan benzoate 
mouth disintegrating tablets. Mouth disintegrating tablets of rizatriptan benzoate were 
prepared using superdisintegrants crospovidone, carboxy methyl cellulose calcium, Indion 
414 and Indion 234 using the direct compression method. The tablets prepared were 
evaluated for thickness, uniformity of weight, content uniformity, hardness, friability, 
wetting time, in vitro and in vivo disintegration time, mouth feel, in-vitro drug release and 
assay by high performance liquid chromatography. The tablets disintegrated in vitro and 
in vivo within 4 to 7 s and 6 to 19 s, respectively. Almost 90% of drug was released from 
all formulations within 20 min. The drug release from the formulations followed first 
order kinetics. Stability studies of the tablets at 40±2°/75%±5% RH for 1 month showed 
non-significant drug loss. The formulation containing combination of crospovidone and 
Indion 234 was found to give the best results. Apart from fulfilling all official and other 
specifications, the tablets exhibited higher rate of release. 
 
Amit Alexander et al. 
50 
(2011) studied the effect of polymers, permeation enhancers and 
specialized components of mucoadhesives. Mucoadhesive polymers have recently gained 
interest among pharmaceutical scientists as a means of improving drug  delivery  by  
promoting  dosage  form  residence  time  and  contact  time  with  the  mucous  
membranes. Mucoadhesion occurs between two surfaces, one of which is a mucous 
membrane and another is drug delivery system.  Pharmaceutical  aspects  of  
mucoadhesion  have  been  the  subject  of  great  interest  during recent  years because 
mucoadhesion could be a solution for bioavailability problems that result from a too short 
length of stay of  the  pharmaceutical  dosage  form  at  the  absorption  site  within  the  
gastro-intestinal  tract.  It  has  been  a  great challenge  to  the  pharmaceutical  sciences  
in  order  to  enhance  localized  drug  delivery  or  to deliver ‘difficult’ molecules  
(proteins  and  oligonucleotides)  into  the  systemic  circulation.  Mucoadhesive  systems  
remain  in  close contact  with  the  absorption  tissue,  the  mucous  membrane,  releasing  
the  drug  at  the  site  of  action  leading  to increase  in  bioavailability  (both  local  and  
systemic  effects). Extending  the  residence  time  of  a  dosage form  at  a particular  site  
and  controlling  the  release  of  drug  from  the  dosage  form  are  useful  especially  for  
achieving controlled  plasma  level  of  the drug as  well  as  improving  bioavailability.  
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The present review describes mucoadhesion, mucoadhesive polymers and use of these 
polymers in designing different types of mucoadhesive drug delivery systems.    
 
Alpana P. Kulkarni et al. 
51 (2012) reported the development of oral disintegrating tablet 
of Rizatriptan benzoate with inhibited bitter taste. Taste masking was done by mass 
extrusion with aminoalkylmethacrylate copolymer, Eudragit EPO, in different ratios. The 
drug: polymer ratio was optimized based on bitterness score and RZB -polymer 
interaction. Taste masking was evaluated by checking the in vitro release of RZB in 
simulated salivary fluid (SSF) of pH 6.8 and by sensory evaluation in human volunteers. 
For formulation of rapid- disintegrating tablets of RZB, the batch that depicted optimum 
release of RZB in SSF was considered. ODTs of Rizatriptan benzoate were prepared by 
using superdisintegrants namely, sodium starch glycolate, crospovidone and 
croscarmellose sodium using the direct compression method. The tablets were evaluated 
for hardness, friability, wetting time, in vitro disintegration time. Eudragit EPO was able 
to mask the bitter taste of Rizatriptan benzoate effectively in 1:1 ratio by mass extrusion 
method. ODTs containing crospovidone (5% w/w) depicted minimum disintegration time. 
Taste evaluation of ODT in human volunteers revealed considerable taste masking, with 
all 6 volunteers, reporting the taste of ODTs as good in comparison with RB. Thus, results 
conclusively demonstrated successful taste masking and rapid disintegration of the 
formulated tablets in the oral cavity with adequate dissolution. The research work suggests 
a rapid, simple and cost effective mass extrusion method for formulation of ODT of 
Rizatriptan benzoate. 
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3. AIM AND OBJECTIVE 
3.1. Aim 
Rizatriptan benzoate is a Serotonin 5-HT 1B/1D receptor agonist. It is clinically used as 
an antimigraine agent.  Rizatriptan benzoate  is  rapidly  absorbed  after  oral  
administration and  has  relatively  low  bioavailability  i.e.  45%  which  is  due  to  high  
first  pass metabolism  via  Mono  amino  oxidase-A  enzyme  and  also  reported  to  be  
degraded  in stomach. It has low permeability with high solubility (BCS-III Class) and 
biological half-life of less than 3 hours and is used orally in dose of 5-10 mg twice or 
thrice a day.
 53
 
 Drug  therapy  of  Migraine  has  to  be  individualized  based  on  severity  & 
frequency  of  attacks,  where  in  the  subject  requires  repeated  or  frequent 
dosing.
52
 
 The  conventional  dosage  forms  available  are  associated  with  low 
bioavailability problems  due  to  extensive  first  pass  metabolism.  
 In  order  to  overcome  these  drawbacks, drugs  can  be  developed  in  form  of 
sublingual drug delivery system.  
 Sublingual delivery of drugs provide an attractive alternative to oral route of drug 
administration, particularly in overcoming deficiencies such as high first pass 
metabolism and drug degradation in the harsh environment.  
 Sublingual tablets have  the advantage  of increased  drug  permeability  time,  
which  in  turn  results  in  better bioavailability and quick onset of action 
 
3.2. OBJECTIVE OF THE PROPOSED RESEARCH WORK 
1. To  carry  out  preformulation  studies  on  drug  and  permeation 
enhancer(s)  and  to  establish their compatibility in formulation by FTIR 
study.  
2. To  formulate  Sublingual tablets  using  varying  concentrations  of 
Rizatriptan benzoate  (drug)  and  permeation enhancer(s)  like  β-
Cyclodextrin,  Chitosan lactate and Sodium lauryl sulphate.  The 
Sublingual tablets will be prepared  by direct compression method.  
3. AIM AND OBJECTIVE 
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3. To study the effect of various factors like permeation enhancer(s)  to drug 
ratio, permeation enhancer(s)  ratio on the response parameters like release 
rate and permeability of drug across  the sublingual route.  
4. To  study  the  release  pattern  and  to  conclude  the  better permeation 
enhancer which enhance the permeability in desired manner.  
 
3.3. PLAN OF THE RESEARCH WORK 
1. Design of the sublingual tablets.  
2. Preformulation Studies 
 Physical compatibility study 
 FTIR study 
3. Phase solubility study of Rizatriptan benzoate. 
4. Preparation of standard curve for Rizatriptan benzoate. 
5. Formulation development 
i. Formulation of varying concentration of β – Cyclodextrin with 
Rizatriptan benzoate. 
ii. Formulations of varying concentration of Chitosan lactate with 
Rizatriptan benzoate. 
iii. Formulation of varying concentration of Sodium lauryl sulphate with 
Rizatriptan benzoate. 
6. Precompression studies of drug and blend 
7. Preparation of tablets 
8. Post – compression evaluation of tablets 
 Physical Characteristics 
 Description 
 Uniformity of Weight 
 Hardness 
 Diameter and Thickness 
 Friability 
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 Drug content 
 Disintegration time  
 Wetting time  
 Uniformity of content 
 In vitro Dissolution study of tablets 
 In vitro Permeation study of tablets in egg membrane. 
 Ex vivo Permeation study of tablets in goat sublingual  mucosa 
9. Evaluation of optimized formulation. 
 
4. RATIONALE OF THE STUDY 
 
Department of Pharmaceutics, Madras Medical College. Page 28 
 
4. RATIONALE OF THE STUDY 
In the present scenario, there is an ever-increasing demand for more patient 
compliant dosage forms. One important innovation in this direction is the development 
of fast dissolving/disintegrating oral dosage forms that dissolve or disintegrate 
instantly upon contact with recipient’s tongue or buccal mucosa. They have proved to 
be ideal for geriatric and pediatric population, people suffering from migraine and for 
drugs undergoing high first pass metabolism. As tablets disintegrate in mouth, this 
could enhance the clinical effect of drug through pregastric absorption from the mouth, 
pharynx and esophagus. This leads to an increase in bioavailability by avoiding first 
pass liver metabolism 
55
. Literature survey also revealed that, bioavailability of drug 
from fast dissolving tablet dosage forms is significantly greater than those observed 
from conventional tablet dosage forms. 
56
 
 
4.1. Rationale for the selection of drug 
53, 57
 
Rizatriptan benzoate is a Serotonin 5-HT 1B/1D receptor agonist. It is clinically used 
as an antimigraine agent.  Rizatriptan benzoate  is  rapidly  absorbed  after  oral  
administration and  has  relatively  low  bioavailability  i.e.  45%  which  is  due  to  high  
first  pass metabolism  via  Mono  amino  oxidase-A  enzyme  and  also  reported  to  be  
degraded  in stomach. It has low permeability with high solubility (BCS-III Class) and 
biological half-life of less than 3 hours and is used orally in dose of 5-10 mg twice or 
thrice a day.   
 
4.2. Rationale for selection of dosage form 
26, 27, 54 
In the present study, attempts will be made to prepare fast dissolving sublingual 
tablet of Rizatriptan benzoate to provide relief to patients who suffer from severe 
migraine attack, enhance the permeability as well as dissolution rate and to improve 
the bioavailability by avoiding first pass metabolism. 
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5. DISEASE PROFILE – MIGRAINE52, 53, 57-60 
5.1. Migraine 58 
Migraine is a recurrent incapacitating neurovascular disorder characterized by 
attacks of debilitating pain associated with photophobia, phonophobia, nausea and 
vomiting. Migraine affects a substantial fraction of world population and is a major cause 
of disability in the work place. Though the pathophysiology of migraine is still unclear, 
three major theories proposed with regard to the mechanisms of migraine are vascular 
(due to cerebral vasodilatation), neurological (abnormal neurological firing which causes 
the spreading depression and migraine) and neurogenic dural inflammation (release of 
inflammatory neuropeptides). The modern understanding of the pathogenesis of migraine 
is based on the concept that it is a neurovascular disorder. The drugs used in the 
treatment of migraine either abolish the acute migraine headache or aim its prevention. 
The last decade has witnessed the advent of Sumatriptan and the Rizatriptan class of 5-
HT1B/1D receptor agonists which have well established efficacy in treating migraine. 
Currently prophylactic treatments for migraine include calcium channel blockers, 5-HT2 
receptor antagonists, beta adrenoceptor blockers and g-amino butyric acid (GABA) 
agonists. Unfortunately, many of these treatments are non-specific and not always 
effective. Despite such progress, in view of the complexity of the aetiology of migraine, 
it still remains undiagnosed and available therapies are underused. 
 
5.2. Pathophysiology of migraine 
59
 
Migraine is characterized by episodes of head pain that is often throbbing and 
frequently unilateral and may be severe. In migraine without aura (previously known as 
common migraine) attacks are usually associated with nausea, vomiting, or sensitivity to 
light, sound, or movement and when treated, the attacks typically last 4 to 72 h. A 
combination of features is required for the diagnosis, but not all features are present in every 
attack or in every patient. These symptoms do distinguish migraine from tension type 
headache, the most common form of primary headache, which is characterized by the 
lack of associated features. Any severe and recurrent headache is most likely a form of 
migraine and should be responsive to antimigraine therapy. In 15% of patients, migraine 
attacks are usually preceded or accompanied by transient focal neurotic symptoms, which 
are usually visual; such patients have migraine with aura (previously known as classic 
migraine. In a recent, large population-based study, 64% of patients with migraine had 
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only migraine without aura, 18% had only migraine with aura and 13% had both types of 
migraine (the remaining 5% had aura without headache). Thus, up to 31% of patients 
with migraine have aura on some occasions, but clinicians who rely on the presence of 
aura for the diagnosis of migraine will miss many cases. 
A recent survey by the World Health Organization (WHO), rates severe migraine, 
along with quadriplegia, psychosis, and dementia, as one of the most disabling chronic 
disorders. This ranking suggests that in the judgment of WHO, a day with severe 
migraine is as disabling as a day with quadriplegia. 
 
5.3. Theories of migraine 
59
 
5.3.1. Vascular theory : In the late 1930‘s, Harold Wolff became the first researcher to 
place migraine on a scientific basis, Wolf measured the diameter of the extra cranial 
(temporal) arteries in patients suffering migraine attacks and found them to be 
dilated. These patients were treated with vasoconstrictors (ergotamine) which 
relieved the pain and decreased the arterial dilation. Although subsequent events 
leading to headache (and associated symptoms) are not completely understood, the 
increased vascular pulsation may activate stretch receptors. This would, in turn 
increase the activity of neuropeptide containing (mainly calcitonin gene-related 
peptide (CGRP) perivascular nerves which may ultimately cause pain and other 
associated symptoms. In line with the finding that carotid arteriovenous 
anastomoses dilatation play a role in the pathogenesis of migraine; it is reasonable 
to believe that compounds which produce a cranioselective vasoconstriction may 
have a potential therapeutic use in the treatment of migraine. In anaesthetized dogs 
and pigs acutely acting antimigraine drugs, ergot alkaloids (ergotamine and 
dihydroergotamine) and triptans (Sumatriptan and second generation triptans) 
produced potent vasoconstriction in the canine and porcine carotid vasculature. 
Further studies demonstrated that mainly 5-HT1B receptors mediate Sumatriptan- 
induced cranial vasoconstriction, involving carotid arteriovenous anastomoses and 
temporal and middle meningeal arteries. 
 
5.3.2. Neurological theory: A second theory of migraine is the neurological theory 
of migraine. This theory suggests that migraine arises as a result of abnormal 
neuronal firing and neurotransmitter release in brain neurons. This theory focuses 
on an explanation for certain symptoms, such as premonitory symptoms occurring 
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prior to an attack (prodrome), which are difficult to explain based on the vascular 
hypothesis. The fact that migraine headaches begin and develop slowly coupled 
to the fact that external factors, such as stress, and hunger can precipitate 
migraine attacks to pathologies arising in the neuronal system, thus supporting a 
neurological basis of migraine. Cortical spreading depression, an expanding 
depolarization of cortical neurons which is well characterized in many species but 
not in man is often suggested to underlie the aura or prodrome associated with 
initiation of migraine attack. During spreading depression, cortical function is 
disrupted subsequent to neuronal depolarization and increased extracellular 
potassium. These cortical changes are thought to be the cause of the transient 
sensory or motor impairments that frequently precede the painful period of a 
migraine attack Many investigators hypothesize that neuronal activation in 
migraine may be mediated by cortical spreading depression (CSD). 
 
5.3.2. Neurogenic theory: This theory demonstrates that blood flow changes similar to 
those known to occur in migraine could be produced by electrically stimulating 
brain stem structures. 
This finding led to the neurogenic theory. Stimulation studies investigated the 
relationship between the trigeminal nerve and the cranial vasculature. Moskowitz 
showed that trigeminovascular axons from blood vessels of the pia mater and dura 
mater release vasoactive peptides producing a sterile inflammatory reaction with 
pain. During this neurogenic inflammation, the trigeminal ganglion is stimulated 
and this induces neurogenic protein extravasation. Vasodilatory peptides then 
released, including calcitonin gene related peptide (CGRP), substance P (SP) and 
neurokinin A. Neurogenic theory is an attempt to reconcile the vascular changes in 
the neuronal dysfunction that may occur in migraine headache and proposes that 
migraine pain is associated with inflammation and dilation of the meninges, 
particularly the dura, a membrane surrounding the brain. Neurogenic dural 
inflammation is thought to result from the actions of inflammatory neuropeptides 
released from the primary sensory nerve terminals innervating the dural blood 
vessels. In fact, the dural membrane surrounding the brain is the source for the 
majority of intracranial pain afferents and dural stimulation produces headache like 
pain in human. Stimulation or inflammation of sensory fibers release the 
inflammatory neuropeptides, substance P and calcitonin gene-related peptide onto 
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dural tissue, where these peptides produce a local response called neurogenic 
inflammation. Neurogenic inflammation may lower the nociceptive threshold 
required to stimulate meningial sensory fibers. According to neurogenic dural 
inflammation theory of migraine, release of these inflammatory neuropeptides in 
the dura-mater during migraine can act on vascular tissues to cause vasodilatation, 
plasma protein extravasation in the surrounding area, endothelial changes, platelet 
aggregation and subsequent release of serotonin and other mediators, white cell 
adhesion and subsequent inflammation. CGRP plays a facilitatory role in this 
process. Whereas substance P induces extravasation via activation of NK1 
receptors, release of CGRP enhances the effects of substance P by increasing dural 
blood flow and by inhibiting an extracellular enzyme that normally can metabolize 
substance P. Therefore, these two sensory neuropeptides act in concert to produce 
painful dural inflammation. Although not reliably demonstrated, increased cranial 
venous concentration of CGRP have been observed during a migraine attack and 
the elevated concentrations of CGRP have returned to normal following treatment 
of the migraine in the serotonergic agonists. This theory is in consistent with the 
proposal that serotonergic agonist alleviate the acute pain of migraine by inhibiting 
the release of substance P and CGRP from trigeminal sensory afferent neurons 
surrounding the meninges. 
 
5.4. Pain mechanisms in migraine 
59
 
The pathogenesis of pain in migraine is not completely understood so far, but 
three key factors merit considerations are: the cranial blood vessels, the trigeminal 
innervation of the vessels, and the reflex connection of the trigeminal system in the 
cranial parasympathetic outflow. The substance of the brain is largely insensate; pain can 
be generated by large cranial vessels, proximal intracranial vessels or by the dura mater. 
These vessels are innervated by branches of the ophthalmic division of the trigeminal 
nerve, whereas the structures of the posterior fossa are innervated by branches of the C2 
nerve roots. In nonhuman primates, stimulation of vascular afferents leads to the 
activation of neurons in the superficial layers of the trigeminal nucleus caudalis in the 
region of the craniomedullary junction and the superficial layers of the dorsal horns C1 
and C2 levels of the spinal cord trigeminocervical complex. Similarly, stimulation of 
branches of C2 activates neurons in the same regions of the brain. The involvement of 
ophthalmic division of the trigeminal nerve and the overlap with structures innervated by 
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C2 explain the common distribution of migraine pain over the frontal and temporal 
regions, as well as involvement of parietal, occipital and high cervical regions by what is, 
in essence, referred pain. Peripheral trigeminal activation in migraine is evidenced by 
release of CGRP, a vasodilator, but the mechanism of generation of pain is not clear. 
Studies in animals suggest that the pain may be caused by a sterile neurogenic 
inflammatory process in the dura mater, but this mechanism has not been clearly 
demonstrated to correlate in humans. The pain may be a combination of an altered 
perception as a result of peripheral or central sterilization of craniovascular input that is 
not usually painful and the activation of feed-forward neurovascular dilator mechanism 
that is functionally specific for the first (ophthalmic) division of the trigeminal nerve. 
 
5.5. Emerging therapies 
58
 
5.5.1. Calcitonin gene-related peptide (CGRP) antagonists 
In the recent past, there has been an upsurge in CGRP research and its notable 
role in migraine pathophysiology. Migraine headache is closely associated with the 
activation of trigeminovascular system. CGRP immunoreactive fibres, originating in the 
trigeminal ganglion, innervate cranial cerebral blood vessels. In animals, stimulation of 
these sensory nerve fibers has been shown to cause antidromic release of CGRP and 
subsequent vasodilatation in the cerebral vasculature. Plasma concentrations of CGRP in 
the jugular venous blood, but not of other neuropeptides were elevated during the 
headache phase of migraine. 
Furthermore, in migraine patients: 
(a) Strong correlation was found between plasma CGRP concentrations and migraine 
headache  
(b) Infusion of CGRP produced a migraine-like headache  
(c) Baseline CGRP levels were considerably higher 
(d) The changes in plasma CGRP levels during migraine attacks significantly 
correlated with the headache intensity. Recently Peterson has demonstrated a 
concentration dependent relaxation in the middle cerebral artery when CGRP was 
applied abluminally, which suggest that CGRP mediated vasodilatation is not 
caused by interaction with luminally situated receptor but more likely by 
abluminal receptor on the smooth muscle cells. Hence, inhibition of CGRP or 
antagonism of CGRP receptors could be a viable therapeutic target for the 
pharmacological treatment of migraine.  
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In line with this concept, an important breakthrough in the field of CGRP is the 
development of potent CGRP receptor antagonist olcegepant (BIBN4096BS). In the in 
vivo animal models of migraine, olcegepant attenuated the vasodilation induced by 
trigeminal stimulation and capsaicin- induced anastomotic dilatation. Data from recently 
published clinical proof of concept study by Olesen demonstrated the effectiveness and 
safety of olcegepant for acute treatment of migraine, in which the response rate was 
found similar to oral triptans. No cardiovascular side effects have been reported 
following administration of olcegepant. The lack of cardiovascular side effects may 
prove to be a major advantage for using CGRP receptor antagonists to treat migraine. 
 
5.5.2. Anticonvulsants 
Migraine and epilepsy share several features and respond to many of the same 
pharmacological agents suggesting that similar mechanism may be involved in their 
pathophysiology, hence new targets are being investigated for the prophylactic therapy of 
migraine. Amongst these, anticonvulsants as a class of drugs hold promise for the 
migraine prophylaxis. These drugs are thought to act through multiple mechanisms 
involving voltage gated ion channels, ligand gated ion channels, GABA (g- amino 
butyric acid), glutamate etc. In the central nervous system, GABA is a major inhibitory 
neurotransmitter and known anticonvulsant drugs like sodium valproate, Topiramate and 
gabapentine have been shown to be effective in preventing migraine through modulation 
of GABA neurotransmission. 
 
5.5.3. Histamine H3 agonists 
In recent study, histamine H3 agonists are evaluated for the safety and efficacy for 
migraine prophylaxis. Milan-Guerrero et al in the first part of their study determined the 
undesirable symptomatic effects of N-alpha-methylhistamine, H3 receptor agonist in 
healthy human volunteers and failed to identify adverse effects and in their second part of 
their study N-alpha-methyl histamine, at doses 1 and 3 Dg was found to be significantly 
reduce the frequency, intensity and duration of migraine attacks as well as the need to 
rescue analgesics in 18 patients. Hence carefully controlled doses of H3 receptor agonist 
may offer an alternative approach to migraine prophylaxis. 
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5.5.4. Botulinum toxin type A  
BoNT-A produced by the bacterium Clostridium botolinium consists of a heavy 
chain and light chain linked by a disulfide bond. BoNT-A binds to pre-synaptic nerve 
terminal and is internalized into the cell, where it inhibits acetylcholine release by 
interfering with vesicle docking. These effects make BoNT-A useful for the treatment of 
many disorders related to excessive muscle contraction, such as strabismus, 
blepharospasm, hemifacial spasm and cervical dystonia. New applications of BoNT-A in 
pain therapy support a mechanism for pain reduction that is more complex than a simple 
secondary effect of muscle relaxation. BoNT-A has been used successfully to treat 
several different types of headaches, including tension type headache, cervicogenic 
headache and migraine. Although some types of headaches may have been relieved by 
the inhibition of muscle contraction at trigger points, the efficacy of BoNT-A in treating 
migraine headache implies a direct action on sensory neurons, with an indirect central 
action. It is believed that release of vasoactive neuropeptides, such as SP and CGRP from 
the trigeminal nerve on to the vasculature produces vasodilatation and plasma protein 
extravasation due to increased permeability of post capillary venules. It is proposed that, 
the effectiveness of BoNT-A for the treatment of migraine in the clinical setting may be 
due to its inhibition of neurogenic inflammation induced by the peripheral release of SP 
and CGRP. 
 
5.5.5. Coenzyme Q10 
There has been recent interest in the role that mitochondria may play in migraine 
pathogenesis. It is clear from the recent studies that at least a subset of migraineurs has a 
dysfunction in mitochondrial energy metabolism. Coenzyme Q10 is an essential element 
of the mitochondrial electron transport chain. It is a naturally occurring, small 
hydrophobic substance that freely moves throughout the membrane transferring electrons 
from the NADH dehydrogenase complex and the succinate-Q-reductase complex to 
cytochrome C. In addition to its actions as an electron carrier, coenzyme Q10 may act as 
antioxidant and help protect the myocardium from post-ischaemic reperfusion injury. If 
mitochondrial dysfunction is playing a role in migraine genesis then coenzyme Q10 
could improve mitochondrial function and thus prevent migraine headaches. This belief 
is not without precedence as riboflavin, in an open label study and a placebo-controlled 
trial has been shown to reduce migraine frequency. Riboflavin is indirectly involved in 
the electron transport chain as a precursor of flavin mononucleotides. Coenzyme Q10 is 
5. DISEASE PROFILE 
 
Department of Pharmaceutics, Madras Medical College. Page 38 
an essential element of the electron transport chain, suggesting that it could also work as 
migraine preventive. 
 
5.5.6. NK-1 receptors 
According to neurogenic inflammation theory of migraine, SP induces dural 
inflammation and increases sensitization to migraine headache pain by stimulating NK-1 
receptors. Lanepitant is a high affinity, non-peptide, competitive NK-1 receptor 
antagonist that acts both peripherally and centrally and reported to be effective in guinea 
pig model of dural inflammation. Thus, NK-1 receptor antagonists may have a role in 
migraine therapy. 
 
5.5.7. Nociceptin 
Nociceptin is an endogenous ligand for the opiate-4 (OP-4) receptor. The OP-4 
receptor abundantly expressed in various CNS structures in rodents, nonhuman primates 
and in humans, supporting the role of nociceptin in multitude of CNS functions, 
including motor and balance control, reinforcement and reward, nociception, the stress 
response, sexual behaviour, aggression and autonomic control of physiologic processes. 
It has been reported that approximately 70% of neurons in the human trigeminal ganglion 
exhibit nociceptin immunoreactivity and express OP-4 receptor mRNA. In these cells 
Nociceptin is co-localized with CGRP and substance P, marker peptides of the 
trigeminovascular system. This distribution suggests that nociceptin may be involved in 
the regulation of neuropeptide release from trigeminal nerve terminals and perhaps in 
migraine. Interestingly, in an animal model, Nociceptin dose-dependently suppressed the 
neurogenic dural vasodilatation, while it had no effect on baseline vessel diameter, also 
in a recent study lower circulating levels of Nociceptin was observed during migraine 
attacks. Hence drugs targeting OP-4 receptor might be a promising alternative in the 
pharmacological treatment of migraine. 
 
5.5.8. Melatonin 
Melatonin is a derivative of essential amino acid tryptophan, synthesized in the 
pineal gland. It has wide therapeutic implications including sleeping disorders, circadian 
rhythm, insomnia in blind people, insomnia in elderly patients, aging and Alzheimer 
disease. It has been observed that some patients reporting their headaches predominantly 
or specifically at a certain period of the day. Both episodic and chronic migraineurs  
5. DISEASE PROFILE 
 
Department of Pharmaceutics, Madras Medical College. Page 39 
 
reported waking up in the morning with headaches or being woken up at night by the 
headache. Also migraine patients without depression had lower levels of melatonin than 
controls. Since, melatonin is involved in cerebrovascular regulation; treatment of 
headache disorders including migraine is promising. Melatonin may also be involved in 
migraine co-morbidity. Insomnia in headache patients is the most likely associated 
condition in migraine to respond to melatonin therapy. However, the data from large 
human trials are yet come to provide a proof-of-concept for the potential role of 
melatonin therapy in migraine.
 58-60
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6.1. DRUG PROFILE 
RIZATRIPTAN BENZOATE 
52, 57, 61, 62 
Chemical structure 
 
Chemical name 
 N,N-Dimethyl-2-[5-(1H-1,2,4-triazol-1-yl-methyl)-1H-indol-3-yl]ethanamine 
benzoate. 
CAS number 
145202-66-0 
Molecular formula 
C22H25N5O2  
Molecular weight 
391.5 
Description 
 White or almost white powder or crystals. 
Solubility 
 Soluble in water, sparingly soluble in ethanol (96 per cent), slightly soluble in 
methylene chloride. 
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Melting point 
 178-180 °C 
Category 
Serotonin 5HT1 receptor agonist; treatment of migraine. 
Pharmacology 
 Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 1B 
and 1D receptors. It is structurally and pharmacologically related to other selective 5-
HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-
HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-
HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1; dopamine2; 
muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief 
of migraine headache. In addition to causing vasoconstriction, experimental data from 
animal studies show that Rizatriptan also activates 5-HT1 receptors on peripheral terminals 
of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the 
antimigrainous effect of Rizatriptan in humans. 
Pharmacokinetics 
Absorption 
 It shows rapid absorption following oral administration. Bioavailability is 45%. 
Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan 
with food will delay by 1 hour the time to reach peak plasma concentration. The rate of 
absorption is not affected by the presence of a migraine attack. 
Distribution  
Rizatriptan is minimally bound (14%) to plasma proteins.  The volume of 
distribution is approximately 140 liters in male subjects, and 110 litters in female subjects. 
Studies in rats indicate that rizatriptan crosses the blood-brain barrier to a limited extent. 
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Protein binding 
 14 % 
Half-life 
 2-3 hours 
Cmax 
 For oral ingestion tablets- 1 to 1.5 hrs 
 For orodispersible tablets- 1.6 to 2.5 hrs  
Metabolism and Elimination   
Rizatriptan is metabolized by monoamine oxidase A isoenzyme (MAO-A) to an 
inactive indole acetic acid metabolite. In addition, several other inactive metabolites are 
formed. An active metabolite, N-monodesmethyl-rizatriptan, with pharmacological 
activity similar to that of the parent compound has been identified in small concentrations 
(14%) in the plasma. 
Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan 
while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass 
metabolism. 
Mechanism of Action   
 Three distinct pharmacological actions have been implicated in the antimigraine 
effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to 
inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei 
cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) 
vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-
HT1B receptor agonism. 
Pharmacodynamics  
Rizatriptan is a selective agonist of serotonin (5-hydroxytryptamine; 5-HT) type 
1B and 1D receptors. It is structurally and pharmacologically related to other selective                 
5-HT1B/1D receptor agonists and has only a weak affinity for 5-HT1A, 5-HT5A, and 5-
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HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 
5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; 
dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates 
with the relief of migraine headache. In addition to causing vasoconstriction, experimental 
data from animal studies show that Rizatriptan also activates 5-HT1 receptors on 
peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may 
also contribute to the antimigrainous effect of Rizatriptan in humans. 
Indication 
 Rizatriptan is indicated for the acute treatment of migraine attacks with or without 
aura, but are not intended for use in prophylaxis of migraine. Treatment should begin as 
soon as possible after onset of a migraine attack. 
Dosage 
The recommended oral dose of rizatriptan is 5–10 mg, repeatable after 2 hours up 
to a maximum dose of 30 mg over a 24-hour period. 
Adverse Effect 
 Dizziness 
 Fainting 
 Heart and Blood Vessel Problems 
 High Blood Pressure 
 Loss of Bowel and Bladder Control 
 Slow Heartbeat 
 Vomiting. 
Precautions and Contraindication 
 Rare but serious cardiac events have been associated with the administration of 5-
HT1 agonists, including coronary artery vasospasm, transient myocardial ischemia, atrial 
and ventricular arrhythmias, and myocardial infarction, predominantly in patients with risk 
factors for coronary artery disease. Rizatriptan are contraindicated in patients with a 
history of significant cardiovascular disease. Because rizatriptan may cause an acute, 
usually small, increase in blood pressure, they also are contraindicated in patients with 
6. MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College. Page 44 
uncontrolled hypertension. Rizatriptan should be used with caution in patients with renal 
or hepatic disease but is not contraindicated in such patients. Rizatriptan are 
contraindicated in patients who are taking MAO inhibitors. Triptans should not be used 
concurrently with (or within 24 hours of) an ergot derivative, nor should one triptan be 
used concurrently or within 24 hours of another. 
Drug Interaction 
Citalopram Increased risk of CNS adverse effects 
 
Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of 
serotonin syndrome. 
 
Dihydroergotamine Possible severe and prolonged vasoconstriction 
 
Ergotamine Possible severe and prolonged vasoconstriction 
 
Escitalopram Increased risk of CNS adverse effects 
 
Fluoxetine Increased risk of CNS adverse effects 
 
Fluvoxamine Increased risk of CNS adverse effects 
 
Isocarboxazid The MAO inhibitor, isocarboxazid, may decrease the metabolism and 
clearance of the serotonin 5-HT receptor agonist, rizatriptan. 
Concomitant therapy is contraindicated. 
 
Methysergide Possible severe and prolonged vasoconstriction 
 
Moclobemide The MAO inhibitor, moclobemide, may decrease the metabolism and 
clearance of the serotonin 5-HT receptor agonist, rizatriptan. 
Concomitant therapy is contraindicated. 
 
Nefazodone Increased risk of CNS adverse effects 
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Paroxetine Increased risk of CNS adverse effects 
 
Phenelzine The MAO inhibitor, phenelzine, may decrease the metabolism and 
clearance of the serotonin 5-HT receptor agonist, rizatriptan. 
Concomitant therapy is contraindicated. 
 
Propranolol Propranolol increases the effect and toxicity of Rizatriptan 
 
Tramadol Increased risk of serotonin syndrome. Monitor for symptoms of 
serotonin syndrome. 
 
Tranylcypromine The MAO inhibitor, Tranylcypromine, may reduce the metabolism 
and clearance of the serotonin 5-HT1D receptor agonist, Rizatriptan. 
Risk of serotonin syndrome and Rizatriptan toxicity. Concomitant 
therapy should be avoided. 
 
Trazodone Increased risk of serotonin syndrome. Monitor for symptoms of 
serotonin syndrome. 
 
Trimipramine Increased risk of serotonin syndrome. Monitor for symptoms of 
serotonin syndrome. 
 
Venlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of 
serotonin syndrome. 
 
Zolmitriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as 
zolmitriptan and rizatriptan, may result in additive vasoconstrictive 
effects. Concomitant use within 24 hours is contraindicated. 
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6.2. EXCIPIENTS PROFILE 
6.2.1. CROSPOVIDONE 
63 
 Non-proprietary Names 
BP: Crospovidone 
PhEur: Crospovidone 
USP-NF: Crospovidone 
Synonyms 
Crospovidonum; Crospopharm ; crosslinked povidone; E1202;Kollidon CL; 
Kollidon CL-M ; Polyplasdone XL ; Polyplasdone XL-10 ; polyvinyl polypyrrolidone; 
PVPP; 1-vinyl-2-pyrrolidinone homopolymer. 
Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
Empirical Formula and Molecular Weight: 
(C6 H9NO) n , > 1 000 000 
The USP32–NF27 describes crospovidone as a water-insoluble synthetic 
crosslinked homopolymer of N-vinyl-2-pyrrolidinone. An\exact determination of the 
molecular weight has not been established because of the insolubility of the material. 
Functional Category 
Tablet disintegrant. 
Description 
Crospovidone is a white to creamy-white, finely divided, free-flowing, practically 
tasteless, odorless or nearly odorless, hygroscopic powder. 
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Solubility 
 Completely insoluble in water, acids, alkalis, and all organic solvents. Hygroscopic 
swells rapidly in water. Rapidly disperses in water, but does not gel even after prolonged 
exposure. 
Applications in Pharmaceutical Formulation or Technology 
Crospovidone is a water-insoluble tablet disintegrant and dissolution agent used at      
2–5% concentration in tablets prepared by direct-compression or wet- and dry-granulation 
methods. It rapidly exhibits high capillary activity and pronounced hydration capacity, 
with little tendency to form gels. Studies suggest that the particle size of crospovidone 
strongly influences disintegration of analgesic tablets. Larger particles provide faster 
disintegration than smaller particles. Crospovidone can also be used as a solubility 
enhancer. With the technique of co-evaporation, crospovidone can be used to enhance the 
solubility of poorly soluble drugs. The drug is adsorbed on to crospovidone in the presence 
of a suitable solvent and the solvent is then evaporated. This technique results in faster 
dissolution rate. 
Stability and Storage conditions 
Since crospovidone is hygroscopic, it should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adducts within solution with sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, 
tannin, and other compounds. The efficacy of some preservatives, e.g. thimerosal, may be 
adversely affected by the formation of complexes with povidone. 
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6.2.2. MICROCRYSTALLINE CELLULOSE 
63 
Nonproprietary Names 
BP: Microcrystalline Cellulose 
JP: Microcrystalline Cellulose 
PhEur: Cellulose, Microcrystalline 
USP-NF: Microcrystalline Cellulose 
Synonyms 
Avicel PH; Cellets ; Celex; cellulose gel; hellulosum microcristalli-num; Celphere 
; Ceolus KG ; crystalline cellulose; E460; Emcocel; Ethispheres ; Fibrocel; MCC Sanaq; 
Pharmacel; Tabulose ; Vivapur. 
Chemical Name and CAS Registry Number: 
Cellulose [9004-34-6] 
Empirical Formula and Molecular Weight: 
(C6H 10O5) n, ≈ 36,000 
Where, 
 n ≈ 220.  
Functional Category 
Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant. 
Description 
Microcrystalline cellulose is a purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particle sizes and moisture grades that have different 
properties and applications. 
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Solubility 
  Insoluble in water, dilute acids, and most organic solvents. Practically insoluble in 
sodium hydroxide. 
Applications in Pharmaceutical Formulation or Technology 
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct compression processes. In addition to its use as a binder/diluent, 
micro-crystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting. 
Stability and Storage conditions 
Microcrystalline cellulose is a stable though hygroscopic material. The bulk 
material should be stored in a well-closed container in a cool, dry place. 
Incompatibilities 
Microcrystalline cellulose is incompatible with strong oxidizing agents. 
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6.2.3. MANNITOL 
63 
Nonproprietary Names 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitol 
USP: Mannitol 
Synonyms 
Cordycepic acid; C*PharmMannidex; E421; Emprove ; manna sugar; D-mannite; 
mannite; mannitolum; Mannogem; Pearlitol. 
Chemical Name and CAS Registry Number: 
D -Mannitol [69-65-8] 
Empirical Formula and Molecular Weight: 
C 6H 14O 6, 182.17 
Functional Category 
Diluent; plasticizer; sweetening agent; tablet and capsule diluent; therapeutic 
agent; tonicity agent. 
Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is 
isomeric with sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free-
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as sweet 
as sucrose, and imparts a cooling sensation in the mouth. Microscopically, it appears as 
orthorhombic needles when crystallized from alcohol. Mannitol shows polymorphism. 
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Solubility 
 Soluble in water, very slightly soluble in ethanol and practically insoluble in ether. 
Applications in Pharmaceutical Formulation or Technology 
Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in tablet 
formulations, where it is of particular value since it is not hygroscopic and may thus be 
used with moisture-sensitive active ingredients. Mannitol may be used in direct-
compression tablet applications, for which the granular and spray-dried forms are 
available, or in wet granulations. Granulations containing mannitol have the advantage of 
being dried easily. Specific tablet applications include antacid preparations, glyceryl 
trinitrate tablets, and vitamin preparations. Mannitol is commonly used as an excipient in 
the manufacture of chewable tablet formulations because of its negative heat of solution, 
sweetness, and ‘ mouth feel ’. In lyophilized preparations, mannitol (20–90% w/w) has 
been included as a carrier to produce a stiff, homogeneous cake that improves the 
appearance of the lyophilized plug in a vial. A pyrogen free form is available specifically 
for this use. Mannitol has also been used to prevent thickening in aqueous antacid 
suspensions of aluminum hydroxide (< 7% w/v). It has been suggested as a plasticizer in 
soft-gelatin capsules, as a component of sustained-release tablet formulations, and as a 
carrier in dry powder inhalers.  
Stability and Storage Conditions 
Mannitol is stable in the dry state and in aqueous solutions. Solutions may be 
sterilized by filtration or by autoclaving and if necessary may be autoclaved repeatedly 
with no adverse physical or chemical effects. In solution, mannitol is neither attacked by 
cold and dilute acids or alkalis nor by atmospheric oxygen in the absence of catalysts. 
Mannitol does not undergo Millard reactions. The bulk material should be stored in a well-
closed container in a cool, dry place. 
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Incompatibilities 
Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride 
or sodium chloride. Precipitation has been reported to occur when a 25% w/v mannitol 
solution was allowed to contact plastic. Sodium cephapirin at 2 mg/mL and 30 mg/mL 
concentration is incompatible with 20% w/v aqueous mannitol solution. Mannitol is 
incompatible with xylitol infusion and may form complexes with some metals such as 
aluminum, copper, and iron. Reducing sugar impurities in mannitol have been implicated 
in the oxidative degradation of a peptide in a lyophilized formation. Mannitol was found to 
reduce the oral bioavailability of cimetidine compared to sucrose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College. Page 53 
 
6.2.4. CHITOSAN LACTATE 
63 
Nonproprietary Names 
BP: Chitosan Hydrochloride 
PhEur: Chitosan Hydrochloride 
Synonyms 
2-Amino-2-deoxy-(1,4)-b- D -glucopyranan; chitosani hydrochlori-dum; 
deacetylated chitin; deacetylchitin;b -1,4-poly-D-glucosamine;poly-D -glucosamine; poly-
(1,4- b- D -glucopyranosamine). 
Chemical Name and CAS Registry Number: 
Poly-b -(1,4)-2-Amino-2-deoxy- D-glucose [9012-76-4] 
Empirical Formula and Molecular Weight: 
Partial deacetylation of chitin results in the production of chitosan, which is a 
polysaccharide comprising copolymers of glucosamine and N -acetylglucosamine. 
Chitosan is the term applied to deacetylated chitins in various stages of deacetylation and 
depolymeriza-tion and it is therefore not easily defined in terms of its exact chemical 
composition. A clear nomenclature with respect to the different degrees of N-deacetylation 
between chitin and chitosan has not been defined,and as such chitosan is not one chemical 
entity but varies in composition depending on the manufacturer. In essence, chitosan is 
chitin sufficiently deacetylated to form soluble amine salts. The degree of deacetylation 
necessary to obtain a soluble product must be greater than 80–85%. Chitosan is 
commercially available in several types and grades that vary in molecular weight by 10 
000–1 000 000, and vary in degree of deacetylation and viscosity. 
Description 
Chitosan occurs as odorless, white or creamy-white powder or flakes. Fiber 
formation is quite common during precipitation and the chitosan may look ‘cottonlike’. 
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Solubility 
 Completely soluble in water at pH < 6.3 and precipitates at pH > 6.5 
Functional Category 
Coating agent; disintegrant; film-forming agent; mucoadhesive; tablet binder; 
viscosity increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
Chitosan is used in cosmetics and is under investigation for use in a number of 
pharmaceutical formulations. The suitability and performance of chitosan as a component 
of pharmaceutical formulations for drug delivery applications has been investigated in 
numerous studies. These include controlled drug delivery applications, use as a component 
of mucoadhesive dosage forms, rapid release dosage forms, improved peptide delivery, 
colonic drug delivery systems, and use for gene delivery. Chitosan has been processed into 
several pharmaceutical forms including gels, films, beads, micro-spheres, tablets, and 
coatings for liposomes. Furthermore, chitosan may be processed into drug delivery 
systems using several techniques including spray-drying, coacervation, direct 
compression, and conventional granulation processes. 
Stability and Storage conditions 
Chitosan powder is a stable material at room temperature, although it is 
hygroscopic after drying. Chitosan should be stored in a tightly closed container in a cool, 
dry place. The PhEur 6.5 specifies that chitosan should be stored at a temperature of 2–88 
C. 
Incompatibilities 
Chitosan is incompatible with strong oxidizing agents. 
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6.2.5. β – CYCLODEXTRIN 63 
Nonproprietary Names 
BP              : Betadex 
Ph. Eur     : Betadex 
USP – NF : Betadex 
Synonyms 
Beta – cycloamylose; Beta – dextrin; Betadexum; Cacamax W7 pharma; 
Cyclohepta amylose; Cyclohepta glucan; Cyclomalto heptose; Kleptose 
Chemical Name and CAS Registry Number: 
β – Cyclodextrin & [585 -39- 9] 
Empirical Formula and Molecular Weight: 
C42H70O35, 1135 
Description 
Cyclodextrins are oligosaccharides containing at least six D–(+)glucopyranose 
units attached by α(1→4) glucoside bonds. β – Cyclodextrin contains 7 glucose units. 
Cyclodextrins occur as white, practically odorless, fine crystalline powders, having a 
slightly sweet taste. Some cyclodextrin derivatives occur as amorphous powders. 
Solubility 
Soluble 1 in 200 parts of propylene glycol, 1 in 50 of water at 20
0
C, 1 in 20 at 
50
0
C; practically insoluble in acetone, ethanol (95%), and methylene chloride. 
Functional Category: 
Solubilizing agent; stabilizing agent. 
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Applications in Pharmaceutical Formulation or Technology 
Cyclodextrins are ‘bucket like’ or ‘cone like’ toroid molecules, with a rigid 
structure and a central cavity, the size of which varies according to the cyclodextrin type; 
The internal surface of the cavity is hydrophobic and outside of the torus is hydrophilic; 
this is due to the arrangement of hydroxyl groups within the molecule. This arrangement 
permits the cyclodextrin to accommodate a guest molecule within the cavity, forming an 
inclusion complex. 
Cyclodextrins may be used to form inclusion complexes with a variety of drug 
molecules, resulting primarily in improvements to dissolution and bioavailability owing to 
enhanced solubility and improved chemical and physical stability. Cyclodextrin inclusion 
complexes have also been used to mask the unpleasant taste of active materials and to 
convert a liquid substance into a solid material. 
β – Cyclodextrin is the most commonly used cyclodextrin, although it is the least 
soluble. It is the least expensive cyclodextrin; is commercially available from a number of 
sources; and is able to form inclusion complexes with a number of pharmaceutical 
interests. β – Cyclodextrin is primarily used in tablet and capsule formulations. 
In oral tablet formulations, β – cyclodextrin may be used in both wet-granulation 
and direct-compression processes. The physical properties of β – Cyclodextrin vary 
depending on the manufacturer. However, β – Cyclodextrin tends to possess poor flow 
properties and requires a lubricant, such as 0.1%w/w Magnesium stearate, when it is 
directly compressed. 
Stability and Storage conditions 
β – Cyclodextrin and other cyclodextrins are stable in solid state if protected from 
high humidity. Cyclodextrins should be stored in a tightly sealed container, in a cool, dry 
place. 
Incompatibilities 
The activity of some antimicrobial preservatives in aqueous solution can be reduced in the 
presence of hydroxypropyl-β-cyclodextrin. 
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6.2.6. SODIUM LAURYL SULFATE 
63 
Nonproprietary Names 
BP: Sodium Lauryl Sulphate 
JP: Sodium Lauryl Sulfate 
PhEur: Sodium Lauril sulfate 
USP-NF: Sodium Lauryl Sulfate 
Synonyms 
Dodecyl alcohol hydrogen sulfate, sodium salt; dodecyl sodium sulfate; 
dodecylsulfate sodium salt; Elfan 240; lauryl sodium sulfate; lauryl sulfate, sodium salt; 
monododecyl sodium sulfate; natrii lauril sulfas; sodium dodecyl sulfate; sodium n-
dodecyl sulfate; sodium lauril sulfate; sodium monododecyl sulfate; sodium monolauryl 
sulfate; SDS; SLS; sulfuric acid monododecyl ester, sodium salt; Texapon K12P. 
Chemical Name and CAS Registry Number: 
Sulfuric acid monododecyl ester sodium salt (1: 1) [151-21-3] 
Empirical Formula and Molecular Weight: 
C 12H 25NaO4S ,  288.38 
The USP32–NF27 describes sodium lauryl sulfate as a mixture of sodium alkyl 
sulfates consisting chiefly of sodium lauryl sulfate [CH3 (CH2)10CH2OSO3Na]. The PhEur  
6.0 states that sodium lauryl sulfate should contain not less than 85% of sodium alkyl 
sulfates calculated as C12H25NaO4S. 
Description 
SLS consists of white or cream to pale yellow-colored crystals, flakes or powder 
having a smooth feel, a soapy, bitter taste, and a faint odor of fatty substances. 
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Solubility 
 Freely soluble in methanol and DMSO; sparingly soluble in water, ethanol and 
acetone; partly soluble in alcohols. 
Functional Category 
Anionic surfactant; detergent; emulsifying agent; skin penetrant; tablet and capsule 
lubricant; wetting agent. 
Applications in Pharmaceutical Formulation or Technology 
Sodium lauryl sulfate is an anionic surfactant employed in a wide range of 
nonparenteral pharmaceutical formulations and cosmetics. 
 It is a detergent and wetting agent effective in both alkaline and acidic conditions. 
In recent years it has found application in analytical electrophoretic techniques: SDS 
(sodium dodecyl sulfate) polyacrylamide gel electrophoresis is one of the more widely 
used techniques for the analysis of proteins; and sodium lauryl sulfate has been used to 
enhance the selectivity of micellar electrokinetic chromatography (MEKC). 
Stability and Storage conditions 
Sodium lauryl sulfate is stable under normal storage conditions. However, in 
solution, under extreme conditions, i.e. pH 2.5 or below, it undergoes hydrolysis to lauryl 
alcohol and sodium bisulfate. The bulk material should be stored in a well-closed 
container away from strong oxidizing agents in a cool, dry place. 
Incompatibilities 
Sodium lauryl sulfate reacts with cationic surfactants, causing loss of activity even 
in concentrations too low to cause precipitation. Unlike soaps, it is compatible with dilute 
acids and calcium and magnesium ions. Sodium lauryl sulfate is incompatible with salts of 
polyvalent metal ions, such as aluminum, lead, tin or zinc, and precipitates with potassium 
salts. Solutions of sodium lauryl sulfate (pH 9.5–10.0) are mildly corrosive to mild steel, 
copper, brass, bronze and aluminum. 
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6.2.7. ASPARTAME 
63 
Nonproprietary Names 
BP: Aspartame 
PhEur: Aspartame 
USP-NF: Aspartame 
Synonyms 
(3 S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-4-oxobutanoic 
acid; 3-amino-N-( a -carboxyphenethyl)succinamic acid N-methyl ester; 3-amino- N-( a -
methoxycarbonylphenethyl) succinamic acid; APM; aspartamum; aspartyl phenylamine 
methyl ester; Canderel ; E951; Equal; methyl N- L -a-aspartyl-L -phenylala-ninate; 
NatraTaste; NutraSweet; Pal Sweet; Pal Sweet Diet; Sanecta; SC-18862; Tri-Sweet. 
Chemical Name and CAS Registry Number 
N- L -a –Aspartyl -L- phenylalanine 1-methyl ester [22839-47-0] 
Empirical Formula and Molecular Weight 
C 14H 18N2 O5 , 294.30 
Description 
Aspartame occurs as a off white, almost odorless crystalline powder with an 
intensely sweet taste. 
Solubility 
 Sparingly soluble in water and slightly soluble in ethanol. 
Functional Category 
Sweetening agent. 
 
6. MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College. Page 60 
 
Applications in Pharmaceutical Formulation or Technology 
Aspartame is used as an intense sweetening agent in beverage products, food 
products, and table-top sweeteners, and in pharmaceutical preparations including tablets, 
powder mixes, and vitamin preparations. It enhances flavor systems and can be used to 
mask some unpleasant taste characteristics; the approximate sweetening power is 180–200 
times that of sucrose. Unlike some other intense sweeteners, aspartame is metabolized in 
the body and consequently has some nutritive value: 1 g provides approximately 17 kJ (4 
kcal). However, in practice, a small quantity of aspartame consumed provides a minimal 
nutritive effect. 
Stability and Storage conditions 
Aspartame is stable in dry conditions. In the presence of moisture, hydrolysis 
occurs to form the degradation products L-aspartyl- L-phenylalanine and 3-benzyl-6-
carboxymethyl-2,5-diketopiperazine with a resulting loss of sweetness. A third-
degradation product is also known, b- L -aspartyl-L-phenylalanine methyl ester. For the 
stability profile at 258
o
 C in aqueous buffers. Stability in aqueous solutions has been 
enhanced by the addition of cyclodextrins, and by the addition of polyethylene glycol 400 
at pH 2. However, at pH 3.5–4.5 stability is not enhanced by the replacement of water 
with organic solvents. Aspartame degradation also occurs during prolonged heat 
treatment; losses of aspartame may be minimized by using processes that employ high 
temperatures for a short time followed by rapid cooling. 
The bulk material should be stored in a well-closed container, in a cool, dry place. 
Incompatibilities 
Differential scanning calorimetry experiments with some directly compressible 
tablet excipients suggests that aspartame is incompatible with dibasic calcium phosphate 
and also with the lubricant magnesium stearate. Reactions between aspartame and sugar 
alcohols are also known. 
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6.2.8. MAGNESIUM STEARATE 
63 
Nonproprietary Names 
BP           : Magnesium stearate 
JP            : Magnesium stearate 
Ph. Eur    : Magnesium stearate 
USP – NF: Magnesium stearate 
Synonyms 
Magnesium octadecanoate, Octadecanoic acid magnesium salt, Stearic acid. 
Chemical Name and CAS Registry Number: 
Octadecanoic acid magnesium salt & [557-04-0] 
Empirical Formula: 
C36H70MgO4  
Functional Category 
Tablet and Capsule lubricant 
Description 
Magnesium stearate is a very fine, light, white, precipitated or milled, having a 
faint odor of stearic acid and a characteristic taste. The powder is greasy to touch and 
readily adheres to the skin. 
Solubility 
Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in 
warm benzene and warm ethanol (95%). 
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Applications in Pharmaceutical Formulations or Technology 
It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25 – 5.0%w/w. It is also used in barrier creams. 
Stability and Storage conditions 
Magnesium stearate is stable and should be stored in a well-closed container in a 
cool, dry place. 
Incompatibilities: 
Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing Aspirin, 
some vitamins and most alkaloidal salts. 
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6. 3. MATERIALS AND METHODS 
The list of API, excipients and their manufacturers and their use in the present study are 
shown in Table 6.1. 
Table 6.1: List of Materials Used 
S.No Drug/Excipient/Chemical Manufacturer/ Supplier Use in Formulation 
1.  Rizatriptan benzoate Aurobindo Pharma Ltd,  
Hyderabad 
Active Pharmaceutical 
Ingredient 
2.  β –Cyclodextrin Madras Pharmaceuticals 
Ltd, Chennai 
 Permeation enhancer 
3.  Chitosan  
( Water Soluble ) 
Panvo Organics Pvt Ltd, 
Chennai 
 Permeation enhancer 
4.  Sodium lauryl sulphate Vin Biotech Systems Ltd, 
Chennai 
 Permeation enhancer 
5.  Avicel 102 Apex Laboratories Pvt Ltd, 
Chennai 
Diluent 
6.  Mannitol Apex Laboratories Pvt Ltd, 
Chennai 
Diluent 
7.  Crospovidone Apex Laboratories Pvt Ltd, 
Chennai 
Super disintegrant 
8.  Magnesium stearate Apex Laboratories Pvt Ltd, 
Chennai 
Lubricant 
9.  Aspartame  Apex Laboratories Pvt Ltd, 
Chennai 
Sweetening agent 
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The list of Instruments/Equipments used in the present study and their manufacturers are 
shown in Table 6.2. 
Table 6.2: List of Instruments/Equipments  
S.No Instruments/Equipments  Manufacturer 
1.  Electronic Weighing Balance Asha Scientific Company, 
Mumbai 
2.  Shifter Pharma Spares, Mumbai 
3.  10- Station Rotary Compression Machine Rimek, India 
4.  Vernier Caliper Mitutoyo, Japan 
5.  Monsanto Hardness Tester Erweka, Mumbai 
6.  Friabilator Electrolab, India 
7.  pH Meter M C Dalal, Chennai 
8.  Tablet Disintegration Apparatus M C Dalal, Chennai 
9.  Dissolution Test Apparatus Veego, Mumbai 
10.  UV-Visible Spectrophotometer Shimadzu, Japan 
11.  Fourier Transform Infra-Red 
Spectrophotometer 
Nicolet 
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6.3.1. Physical Compatibility Study 
 The physical admixture of the drug and excipients expected to be present in 
the final product were taken in 2 ml glass vials and sealed, and the glass vials were kept at 
room temperature and at 40
0
 ± 2
0
C/75% ± 5% RH for 1 month. At the end of every ten 
days, the samples were withdrawn and analyzed for color change. 
64 
6.3.2. Chemical Compatibility Study 
 Infrared spectroscopy was studied using FTIR spectrophotometry and the 
spectrum was recorded in wave number region of 4000 to 400cm
-1
. The procedure 
consisted of dispersing the sample (drug alone, mixture of drug and the optimized 
formulation) in KBr and compressed into discs by applying a pressure of 5 Tons for 5 
minutes in a hydraulic press. The pellet was placed in the light path and the spectrum was 
recorded. 
65 
 
6.3.3. Preparation of Buffer and Reagents 
66 
6.3.3.1 Preparation of Sodium hydroxide solution (0.2 M) 
8 g of Sodium hydroxide was dissolved in about 700 ml of distilled water and 
volume was made up to 1000 ml with distilled water. 
6.3.3.2 Preparation of Potassium dihydrogen phosphate solution (0.2 M) 
Potassium dihydrogen phosphate (27.218 g) was dissolved in about 700 ml of 
distilled water and the volume was made up to 1000 ml with distilled water. 
6.3.3.3 Preparation of Phosphate buffer solution (pH 6.8) 
50.0 ml of 0.2 M Potassium dihydrogen phosphate was taken in a 100 ml 
volumetric flask, to which 22.4 ml of 0.2 M sodium hydroxide was added and volume was 
made up to the mark with distilled water. 
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6.3.4. Standard Curve for Rizatriptan benzoate 
51 
6.3.4.1. Standard Curve in Phosphate buffer pH 6.8 
100 mg of Rizatriptan benzoate was weighed and transferred to 100 ml standard 
flask. It was dissolved in phosphate buffer pH 6.8 and made up to the volume with 
phosphate buffer pH 6.8, to get a concentration of 1 mg/ml. From the stock solution, 10 ml 
was taken and diluted to 100 ml with phosphate buffer pH 6.8 to get a concentration of 
100 µg/ml. The above solution was further diluted with phosphate buffer to get 
concentrations of 1, 2, 3, 4 and 5 µg/ml. The absorbance of the resulting solutions was 
measured at 226 nm using UV-Visible Spectrophotometer taking phosphate buffer pH 6.8 
as blank. 
6.3.5. Preformulation Parameters 
39, 51
 
The properties of the tablets like weight variation, hardness, friability, 
disintegration time, dissolution profile and content uniformity depends on the powder 
parameters. Properties of powder, which are of most importance, are Bulk density, 
Hausner ratio and Compressibility index etc. These parameters were evaluated on a 
laboratory scale for optimum production with respect to quality and quantity. 
 
Prior to compression into tablets, the blend was evaluated for following properties. 
6.3.5.1. Angle of Repose 
Angle of repose was determined by using funnel method. Powder was poured from 
a funnel that can be raised vertically until a maximum cone height, h, was obtained. 
Diameter of heap, D, was measured. The angle of repose, θ, was calculated by formula 
 
          
                                     
Where, θ is the angle of repose 
 h is the height of pile 
 r is the radius of the pile 
tan θ = h / r 
 
θ = tan
-1
 (h / r) 
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Table 6.3: Relationship between Angle of Repose and Flowability 
67
 
Angle of Repose Flowability 
 
25-30 Excellent 
31-35 Good 
36-40 Fair 
41-45 Passable 
46-55 Poor 
56-65 Very Poor 
>65 Very Very Poor  
 
6.3.5.2. Bulk Density 
 Apparent bulk density was determined by pouring presieved drug excipient 
blend into a graduated cylinder and measuring the volume and weight “as it is”. It is 
expressed in g/mL and is given by 
 
       
Where, M is the mass of the powder 
  V0   is the volume of the powder 
 
6.3.5.3. Tapped Density 
It was determined by placing a graduated cylinder, containing a known mass of 
drug- excipient blend, on mechanical tapping apparatus. The tapped volume was 
measured by tapping the powder to constant volume. It is expressed in g/mL and is given 
by 
 
Where, M is the mass of powder 
  Vt   is the volume of powder 
 
6.3.5.4. Compressibility Index or Carr’s Index 
It is expressed in percentage and is calculated by using the formula, 
Db = M / V0 
 
Dt = M / Vt 
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Where, Dt is the Bulk density in g/mL 
Db is the Tapped density in g/mL 
6.3.5.5. Hausner’s Ratio 
It is the ratio of tapped density to bulk density. It is calculated by the following 
formula: 
   
Where, Db  is the Bulk Density in g/mL 
Dt is the Tapped Density in g/mL 
Table 6.4: Values of Carr’s Index, Hausner’s Ratio 67 
Carr’s Index Flow Property Hausner’s Ratio 
<10 Excellent 1.00 – 1.11 
11 – 15 Good 1.12 – 1.18 
16 -20 Fair 1.19 – 1.25 
21 – 25 Passable 1.26 – 1.34 
26 – 31 Poor 1.35 – 1.45 
32 – 37 Very Poor 1.46 – 1.59 
>38 Very, very Poor >1.60 
 
6.3.6. Formulation of Tablets 
26, 27 
Direct Compression is the process by which tablets are compressed directly from 
mixtures of the drug and excipients without any preliminary treatment. In this process, 
directly compressible diluents like Mannitol and Microcrystalline Cellulose are mixed 
with the drug and other excipients to produce a uniform mixture and compressed into 
tablet. An important feature of direct compression diluents is their dilution potential.
 
Composition of sublingual tablet of Rizatriptan benzoate by direct compression is 
shown in table 6.5. All the ingredients were passed through 60# mesh sieve. Required 
Carr’s Index, CI = [(Dt – Db)/Dt]  X 100 
Hausner’s Ratio, HR = Dt / Db 
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quantity of drug and excipient mixed thoroughly in a polythene bag. Finally the 
magnesium stearate was added and mixed thoroughly to get free flowing powder. The 
blend was compressed using rotary tablet compression machine with 8 mm punch. 
Figure 6.1: Schematic representation of formulation development of Rizatriptan 
benzoate Sublingual Tablets 
26, 27
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
           
            
            
            
            
            
Rizatriptan benzoate, 
Mannitol, Avicel 102, 
Crospovidone, Aspartame 
Blend 
Preformulation 
Study of drug and 
blends 
Blend, Chitosan,                    
β- Cyclodextrin and 
Sodium lauryl sulphate  
Direct Compression 
Lubrication 
Rizatriptan benzoate 
sublingual  Tablets 
 
Post Compression Study 
Sieving 
6
. M
A
T
E
R
IA
L
S
 A
N
D
 M
E
T
H
O
D
S
 
 D
ep
a
rtm
en
t o
f P
h
a
rm
a
ceu
tics, M
a
d
ra
s M
ed
ica
l C
o
lleg
e. 
P
a
g
e 7
0
 
T
a
b
le 6
.5
: C
o
m
p
o
sitio
n
 o
f R
iza
trip
ta
n
 b
en
zo
a
te S
u
b
lin
g
u
a
l T
a
b
lets 2
6
, 2
7 
S
.N
O
 
IN
G
R
E
D
IE
N
T
S
 
F
-1
*
 
F
-2
*
 
F
-3
*
 
F
-4
*
 
F
-5
*
 
F
-6
*
 
F
-7
*
 
F
-8
*
 
F
-9
*
 
1
. 
 
R
izatrip
tan
 b
en
zo
ate*
*
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
1
4
.5
 
2
. 
 
C
ro
sp
o
v
id
o
n
e 
9
 
9
 
9
 
9
 
9
 
9
 
9
 
9
 
9
 
3
. 
 
A
v
icel 1
0
2
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
3
0
.2
5
 
4
. 
 
M
an
n
ito
l 
9
2
.5
 
9
1
 
8
9
.5
 
9
2
.5
 
9
1
 
8
9
.5
 
9
2
.5
 
9
1
 
8
9
.5
 
5
. 
 
B
eta-c
y
clo
d
ex
trin
 
1
.5
 
3
 
4
.5
 
- 
- 
- 
- 
- 
- 
6
. 
 
C
h
ito
san
 
- 
- 
- 
1
.5
 
3
 
4
.5
 
- 
- 
- 
7
. 
 
S
o
d
iu
m
 lau
ry
l su
lp
h
ate 
- 
- 
- 
- 
- 
- 
1
.5
 
3
 
4
.5
 
8
. 
 
A
sp
artam
e 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
0
.7
5
 
9
. 
 
M
ag
n
esiu
m
 stearate 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
1
.5
 
 
T
o
tal w
eig
h
t 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
1
5
0
 
 
*
 w
eig
h
t in
 m
g
     *
*
 E
q
u
iv
alen
t 1
0
 m
g
 R
izatrip
tan
 
 
6. MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College. Page 71 
 
6.3.7. Evaluation of Tablets 
26, 27
 
6.3.7.1. Description
 
Ten tablets were selected randomly and placed in a petridish. The tablets were 
observed from both the sides for colour, shape and appearance. 
6.3.7.2. Uniformity of Weight 
Twenty tablets were selected at random from each batch. The individual tablets 
were weighed and the average weight was determined. The individual weight was 
compared with the average weight. The variation in weight of tablets permissible is given 
in Table 6.6 
Table 6.6: Uniformity of Weight 
66, 67
 
S.No Average weight of a tablet % Deviation 
1. 80 mg or less 10 
2. More than 80 mg but less than 250 mg 7.5 
3. 250 mg or more 5 
 
6.3.7.3. Friability 
20 tablets were weighed and placed in the Roche friabilator test apparatus, the 
tablets were exposed to rolling and repeated shocks, resulting from free falls within the 
apparatus. After 100 evolutions, the tablets were de-dusted and weighed again. The 
friability was determined as the percentage loss in weight of the tablets. 
 
 
Where,  
W is the weight of the tablets after the test 
W0 is the weight of the tablets before the test 
Percentage Friability = (1-W/W0) X 100 
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6.3.7.4. Hardness 
Hardness was measured using the Monsanto hardness tester. The pressure required 
to break diametrically placed matrix tablet, by a coiled spring was measured. 
 
6.3.7.5. Dimensions 
The thickness and diameter of the tablets were determined using a Vernier caliper. 
Three tablets from each formulation were used and average values were calculated. 
 
6.3.7.6. In-vitro Disintegration Studies 
Initially the disintegration time for sublingual tablets was measured using the 
conventional test for tablets as described in the pharmacopoeia. Tablets are placed in the 
disintegration tubes and time required for complete disintegration, that is without leaving 
any residues on the screen is recorded as disintegration time. 
A modified method was also used to check the disintegration time. A about 6-8 mL 
of phosphate buffer 6.8 pH was taken in 10 mL of measuring cylinder .Tablet was placed 
in the cylinder and complete dispersion of tablet in the cylinder was recorded as the 
disintegration time. 
 
6.3.7.7. Wetting Time
 27 
A piece of tissue paper folded twice was placed in a small Petri dish (ID = 6.5 cm) 
containing 6 mL of simulated saliva pH, a tablet was put on the paper containing amaranth 
powder on the upper surface of the tablet, and the time required for formation of pink 
color was measured as wetting time. Three trials for each batch were performed and 
standard deviation was also determined. 
 
6.3.7.8. Drug Content Uniformity 
Twenty tablets were accurately weighed and finely powdered. A quantity 
equivalent to 20 mg of Rizatriptan benzoate was transferred to a 100 mL volumetric flask. 
To it, 50 mL of Phosphate buffer 6.8 was added and shaken to dissolve the drug. The 
solution was filtered and residue was washed with 25 mL of Phosphate buffer 6.8. The 
washing obtained was added to initial filtrate and volume was made upto 100 mL with 
Phosphate buffer 6.8. From the above solution 5 mL of stock solution was diluted to 100 
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mL. Again from second solution 10 mL of stock solution was diluted to 100 mL which 
gives 1 mcg/mL concentration. The drug content was determined spectrophotometrically 
at 226 nm. 
 
6.3.7.9. In vitro Dissolution Studies 
27
 
Dissolution studies were carried out for all the formulations in USP paddle method 
(Apparatus 2) using Phosphate buffer 6.8, as the dissolution medium (900 mL) at 50 Rpm 
and 37 ± 0.5 ºC. Samples were periodically withdrawn at suitable time intervals and 
volume replaced with equivalent amounts of plain dissolution medium. The samples were 
analyzed spectrophotometrically at 226 nm. 
 
6.3.7.10. In vitro Permeation study 
26 
 The open ended tube was used in the drug permeation study. The open ended tube 
enables in vitro analysis of drugs movement across a membrane using a two-compartment 
model. The donor compartment contains the formulation, a non-rate limiting membrane 
(semi permeable membrane) separates the compartments and supports the formulation. 
The samples were withdrawn from the beaker at regular intervals and the drug was 
quantified using UV spectrophotometer. The study was used to determine the rate and 
quantity of drug released from formulation containing Rizatriptan benzoate sublingual 
tablet.  
 
6.3.7.11. Ex vivo permeation study
 26 
i. Preparation of Excised Tissue 
Goat buccal mucosa was obtained from the local slaughterhouse. The 
buccal mucosa was carefully removed from buccal cavity by cutting and 
pulling the mucosa from the cavity using forceps. The removed buccal mucosa 
was then immersed in Ringer’s solution. 
ii. Release Pattern of Drug from Sublingual Tablets  
The open ended tube was used for release study. One side of the open 
ended tube one side was tightly tied with buccal mucosa and filled with drug 
solution. It acts as donor compartment. The open ended tube was immersed in 
receiver compartment beaker containing 200 mL of phosphate buffer pH 6.8 
solution. The whole setup was maintained at 37
o
 C and stirrer was allowed to 
rotate at 50 rpm. At predetermined interval, 5 mL of sample was taken for 2 
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hours and simultaneously replaced with same volume of fresh buffer solution. 
Collected samples were suitably diluted and drug concentration was estimated 
using Shimadzu UV spectrophotometer at 226 nm. 
 
Figure 6.2. Ev-vivo evaluation on goat sublingual mucosa 
 
6.3.7.12. Stability Study 
68
 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity, and light, and to establish a retest for 
the drug substance or a shelf life for the drug product and recommended storage 
conditions. The storage conditions used for stability study was accelerated condition (40 ± 
2 °C / 75 ± 5 %). 
Stability study was carried out for the optimized formulations. Tablets of 
optimized formulation were striped packed and kept in humidity chamber for 90 days at 
the above mentioned temperature. Samples were withdrawn at monthly interval and 
analyzed for following parameters: 
a. Dissolution and Permeability profile  
b. Disintegration and Wetting time profile 
c.  Assay  
d. Test for other physical parameters (Hardness, Thickness, Diameter and Friability).  
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7. RESULTS AND DISCUSSION 
7.1. PREFORMULATION STUDIES 
7.1.1. Solubility 
66
 
 Rizatriptan benzoate is freely soluble in water, sparingly soluble in ethanol (96 
per cent), slightly soluble in methylene chloride.  It is also soluble in Phosphate Buffer 
pH-6.8. 
 
7.1.2. Compatibility Study of Drug and Excipients  
 The compatibility between the drug and excipients was studied by FT-IR spectra. 
The position of peak in FT-IR spectra of pure Rizatriptan benzoate was compared with 
those in FT-IR spectra of Rizatriptan benzoate plus excipients. It was observed that, there 
was no disappearance or shift in peak position of Rizatriptan benzoate in any spectra of 
drug and excipients, which proved that the drug and excipients were compatible. Hence, 
it can be concluded that the drug can be used with the selected excipients without causing 
instability in the formulation. The data obtained is shown in Table 7.2 to 7.10. The 
spectra are reported in Figures 7.1 to 7.9. 
Table 7.1: Physical compatibility study of drug and excipients  
S.No 
Drug and 
Excipients 
Description and Conditions 
Initial Room temperature 40±2ºC / 75±5%RH 
10 
Days 
20 
Days 
30 
Days 
10 
Days 
20 
Days 
30 
Days 
1.  Rizatriptan 
benzoate 
White Coloured 
Powder 
NC NC NC NC NC NC 
2.  β -Cyclodextrin White Crystalline 
Powder 
NC NC NC NC NC NC 
3.  RZB + β -
Cyclodextrin 
White Yellow 
Coloured Powder 
NC NC NC NC NC NC 
4.  Chitosan Yellowish – White 
Powder 
NC NC NC NC NC NC 
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5.  RZB + Chitosan Pale Yellow 
Coloured Powder 
NC NC NC NC NC NC 
6.  Sodium lauryl 
sulphate 
White Coloured 
Powder 
NC NC NC NC NC NC 
7.  RZB + Sodium 
lauryl sulphate 
White Coloured 
Powder 
NC NC NC NC NC NC 
8.  Crospovidone White Coloured 
Powder 
NC NC NC NC NC NC 
9.  RZB + 
Crospovidone 
White Coloured 
Powder 
NC NC NC NC NC NC 
10.  Avicel 102 White Coloured 
Powder 
NC NC NC NC NC NC 
11.  RZB + 
Avicel102 
White Coloured 
Powder 
NC NC NC NC NC NC 
12.  Mannitol White Crystalline 
Powder 
NC NC NC NC NC NC 
13.  RZB + Mannitol White Coloured 
Powder 
NC NC NC NC NC NC 
14.  Aspartame white Coloured 
Powder 
NC NC NC NC NC NC 
15.  RZB + 
Aspartame 
White Coloured 
Powder 
NC NC NC NC NC NC 
16.  Magnesium 
stearate 
White Coloured 
Powder 
NC NC NC NC NC NC 
17.  RZB + 
Magnesium 
stearate 
White Coloured 
Powder 
NC NC NC NC NC NC 
 
The physical compatibility study was performed and the results showed that there 
were no signs of incompatibility. The drug and the excipients are physically compatible.
65 
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7.1.3. FTIR Study – Identification and Compatibility of Drug and Excipients 
The identification of drug and the compatibility between the drug and excipients 
was carried out using FTIR. The FTIR spectra of the pure drug, drug excipient mixtures 
and tablet powder are shown in Figures 7.1 to 7.9 and Tables 7.2 to 7.10.     
Figure 7.1: FTIR Spectrum of Rizatriptan benzoate 
 
Table 7.2: FTIR Spectrum of Rizatriptan benzoate 
Wave Number (cm
-1
) Interpretation 
3124 -OH Stretching (Carboxylic acid) 
3024 -C-H Stretching (aliphatic) 
2923 -C-H Stretching 
1774 -C=O Stretching ( Carboxylic acid) 
1604 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1288 -C-C Stretching (Aliphatic) 
1064 -C-N Stretching 
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Figure 7.2: FTIR Spectrum of Rizatriptan benzoate and β-cyclodextrin 
 
Table 7.3: FTIR Spectrum of Rizatriptan benzoate and β-cyclodextrin 
Wave Number (cm
-1
) Interpretation 
3371 -OH Stretching (Carboxylic acid) 
2923 -C-H Stretching 
2160 -C=O Stretching ( Carboxylic acid) 
2160 -C=O Stretching ( Carboxylic acid) 
1627 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1157 -C-C Stretching (Aliphatic) 
1064 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with β-
cyclodextrin showed no shift and no disappearance of characteristic peaks of drug. This 
suggests that there is no interaction between the drug and β-cyclodextrin.27 
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Figure 7.3: FTIR Spectrum of Rizatriptan benzoate and Chitosan 
 
Table 7.4: FTIR Spectrum of Rizatriptan benzoate and β-cyclodextrin 
Wave Number (cm
-1
) Interpretation 
3278 -OH Stretching (Carboxylic acid) 
3031 -C-H Stretching (aliphatic) 
2916 -C-H Stretching 
1805 -C=O Stretching ( Carboxylic acid) 
1604 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1288 -C-C Stretching (Aliphatic) 
1064 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Chitosan 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that 
there is no interaction between the drug and Chitosan.
 27 
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Figure 7.4: FTIR Spectrum of Rizatriptan benzoate and Sodium lauryl sulphate 
 
Table 7.5: FTIR Spectrum of Rizatriptan benzoate and Sodium lauryl sulphate 
Wave Number (cm
-1
) Interpretation 
3124 -OH Stretching (Carboxylic acid) 
2923 -C-H Stretching 
1805 -C=O Stretching ( Carboxylic acid) 
1612 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1218 -C-C Stretching (Aliphatic) 
1080 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Sodium 
lauryl sulphate showed no shift and no disappearance of characteristic peaks of drug. This 
suggests that there is no interaction between the drug and Sodium lauryl sulphate.
 27 
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Figure 7.5: FTIR Spectrum of Rizatriptan benzoate and Avicel 102 
 
   Table 7.6: FTIR Spectrum of Rizatriptan benzoate and Avicel 102 
Wave Number (cm
-1
) Interpretation 
3340 -OH Stretching (Carboxylic acid) 
2908 -C-H Stretching 
1805 -C=O Stretching ( Carboxylic acid) 
1612 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1164 -C-C Stretching (Aliphatic) 
1056 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Avicel 102 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that 
there is no interaction between the drug and Avicel 102.
 27 
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Figure 7.6: FTIR Spectrum of Rizatriptan benzoate and Mannitol  
 
Table 7.7: FTIR Spectrum of Rizatriptan benzoate and Mannitol 
Wave Number (cm
-1
) Interpretation 
3286 -OH Stretching (Carboxylic acid) 
2947 -C-H Stretching (aliphatic) 
2908 -C-H Stretching 
1743 -C=O Stretching ( Carboxylic acid) 
1604 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1280 -C-C Stretching (Aliphatic) 
1080 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Mannitol 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that 
there is no interaction between the drug and Mannitol.
 27 
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Figure 7.7: FTIR Spectrum of Rizatriptan benzoate and Crospovidone   
 
Table 7.8: FTIR Spectrum of Rizatriptan benzoate and Mannitol 
Wave Number (cm
-1
) Interpretation 
3147 -OH Stretching (Carboxylic acid) 
3024 -C-H Stretching (aliphatic) 
2923 -C-H Stretching 
1805 -C=O Stretching ( Carboxylic acid) 
1612 -C-C Stretching ( Aromatic ) 
1566 -C=N Stretching (Hetero Aromatic) 
1288 -C-C Stretching (Aliphatic) 
1064 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with 
Crospovidone showed no shift and no disappearance of characteristic peaks of drug. This 
suggests that there is no interaction between the drug and Crospovidone.
 27 
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Figure 7.8: FTIR Spectrum of Rizatriptan benzoate and Aspartame 
 
 Table 7.9: FTIR Spectrum of Rizatriptan benzoate and Aspartame 
Wave Number (cm
-1
) Interpretation 
3116 -OH Stretching (Carboxylic acid) 
3031 -C-H Stretching (aliphatic) 
2947 -C-H Stretching 
1874 -C=O Stretching ( Carboxylic acid) 
1658 -C-C Stretching ( Aromatic ) 
1550 -C=N Stretching (Hetero Aromatic) 
1265 -C-C Stretching (Aliphatic) 
1072 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Aspartame 
showed no shift and no disappearance of characteristic peaks of drug. This suggests that 
there is no interaction between the drug and Aspartame.
 (27) 
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Figure 7.9: FTIR Spectrum of Rizatriptan benzoate and Magnesium stearate 
 
Table 7.10: FTIR Spectrum of Rizatriptan benzoate and Magnesium stearate 
Wave Number (cm
-1
) Interpretation 
3255 -OH Stretching (Carboxylic acid) 
3024 -C-H Stretching (aliphatic) 
2916 -C-H Stretching 
1797 -C=O Stretching ( Carboxylic acid) 
1542 -C-C Stretching ( Aromatic ) 
1465 -C=N Stretching (Hetero Aromatic) 
1296 -C-C Stretching (Aliphatic) 
1064 -C-N Stretching 
 
The peaks observed in the FTIR spectrum of Rizatriptan benzoate with Magnesium 
stearate showed no shift and no disappearance of characteristic peaks of drug. This 
suggests that there is no interaction between the drug and Magnesium stearate.
 27 
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7.1.4. Standard Curve of Rizatriptan benzoate 
51
 
The absorbance of the drug in different concentrations in phosphate buffer pH 6.8 
was measured at a wavelength of 226 nm. The results are given in Table 7.11. The 
standard curves plotted using the absorbance of various concentrations is shown in Figure 
7.10. 
Table 7.11: Data for Standard curve of Rizatriptan benzoate 
 
Figure 7.10: Standard Curve of Rizatriptan benzoate in phosphate buffer pH 6.8 
 
Figure 7.10. Standard curve of Rizatriptan benzoate 
y = 0.1267x + 0.0049 
R² = 0.9996 
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Concentration (mcg/mL) 
S.No 
Concentration 
(mcg/ mL) 
Absorbance 
Mean ± SD 
SC-1 SC-2 SC-3 
1.  1 0.134 0.130 0.133 0.132 ± 0.0016996 
2.  2 0.257 0.268 0.268 0.264 ± 0.0051854 
3.  3 0.382 0.396 0.393 0.390 ±  0.0060184 
4.  4 0.501 0.511 0.508 0.506 ± 0.0041899 
5.  5 0.632 0.641 0.638 0.637 ± 0.0037416 
 Regression 0.99991 0.9995 0.9996 0.99967 ± 0.0001745 
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7.1.5. Pre-compression studies of the drug and powder blends 27, 67 
The results of the pre-compression study of the drug and the powder blends are 
given in Table 7.12 and Figures 7.11 to 7.15. 
Table 7.12: Pre-compression study of drug and powder blends 
Drug/ 
Powder 
blends 
Bulk 
density* 
(g/cm
3
) 
Tapped 
density* 
(g/cm
3
) 
Compressibilit
y index* (%) 
Hausner’s 
ratio* 
Angle of 
Repose* (θ) 
RZB 0.625±0.012 0.7142±0.024 12.14±0.045 1.142±0.063 33.05±0.047 
F1 0.500±0.047 0.5555±0.015 10.00±0.024 1.111±0.017 29.75±0.054 
F2 0.500±0.055 0.5454±0.032 08.3±0.038 1.099±0.009 29.30±0.026 
F3 0.500±0.023 0.5395±0.067 07.33±0.016 1.079±0.025 28.89±0.054 
F4 0.500±0.041 0.5454±0.052 08.33±0.037 1.079±0.052 29.00±0.035 
F5 0.500±0.016 0.5357±0.043 06.66±0.021 1.071±0.038 28.89±0.062 
F6 0.500±0.047 0.5319±0.068 05.99±0.059 1.063±0.027 29.17±0.028 
F7 0.500±0.038 0.5260±0.016 05.00±0.028 1.052±0.045 29.40±0.063 
F8 0.500±0.054 0.5357±0.047 06.66±0.015 1.071±0.029 29.29±0.037 
F9 0.500±0.019 0.5261±0.035 05.00±0.012 1.052±0.053 29.67±0.046 
*Mean±SD (n=3) 
The drug has good flow property while the powder blends have excellent flow 
property.
4
 Hence, the tablets were prepared by direct compression technique. 
 
 
 
7. RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College. Page 88 
 
Figure 7.11: Bulk density of drug and powder blend 
 
The bulk density of the drug was found to be 0.625 g/cm
3
. The bulk density of the 
powder blend of various formulations ranged from 0.5013 g/cm
3
 to 0.5 g/cm
3
. 
Figure 7.12: Tapped density of drug and powder blend 
 
The tapped density of drug was found to be 0.7142 g/cm
3
. The tapped density of 
various formulations ranged from 0.5555 g/cm
3
 to 0.5261 g/cm
3
. 
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Figure 7.13: Compressibility Index of drug and powder blend 
 
The compressibility index of the drug was found to be 12.14%. The 
compressibility index of various formulations ranged from 10% to 5%, showing excellent 
flow property. 
Figure 7.14: Hausner’s ratio of drug and powder blend 
 
The Hausner’s ratio of the drug was found to be 1.142. The Hausner’s ratio of 
various formulations ranged from 1.111 to 1.052 showing excellent flow property.
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Figure 7.15: Angle of repose of drug and powder blend 
 
The angle of repose of the drug was found to be 33.05⁰. The angle of repose of 
various formulations ranged from 29.75⁰ to 29.67⁰ showing excellent flow property.  
 
7.2. POST-COMPRESSION EVALUATION OF SUBLINGUAL TABLETS 
7.2.1. Description 
The tablets were white coloured, round and flat faced with bevel edged 
bisect.   
7.2.2. Thickness and Diameter 66 
Thickness and diameter of the nine formulations is given in Table 7.13. 
The thickness and diameter of the tablets is 3.2 mm and 8mm respectively. 
The tablets (F-1 to F-9) have uniform thickness and diameter.
 66 
7.2.3. Hardness  
Hardness of the nine formulations is given in Table 7.13. 
26
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The hardness of the tablets ranged from 4.2 kg/cm
2 
to 4.3 kg/cm
2
. The 
tablets (F-1 to F-9) have sufficient hardness to withstand transport and handling.
 66
 
 
Table 7.13: Thickness, Diameter and Hardness of Sublingual tablets 
Formulations Thickness* (mm) Diameter* (mm) Hardness* kg/cm
2
 
F-1 3.2±0.0 8.0±0.0 4.3±0.2236 
F-2 3.2±0.0 8.0±0.0 4.2±0.2236 
F-3 3.2±0.0 8.0±0.0 4.3±0.1095 
F-4 3.2±0.0 8.0±0.0 4.2±0.1414 
F-5 3.2±0.0 8.0±0.0 4.2±0.0894 
F-6 3.2±0.0 8.0±0.0 4.3±0.2236 
F-7 3.2±0.0 8.0±0.0 4.2±0.3536 
F-8 3.2±0.0 8.0±0.0 4.2±0.2739 
F-9 3.2±0.0 8.0±0.0 4.2±0.2608 
*Mean±SD (n=5) 
7.2.4. Drug content 
The content of active ingredient in various formulations is given in Table 7.14. 
The percentage of drug content ranged from 95.20%w/w to 102.50%w/w. All the 
formulations comply with the official standards.
 66
 
7.2.5. Friability 
The friability of various formulations is given in Table 7.14. 
The percentage friability of various formulations ranged from 0.3123% to 
0.9897%. The percentage friability is within the limit.
66
 
7.2.6. Uniformity of Weight 
The tablets were tested for uniformity of weight and the results are given in 
Table 7.14. 
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The weight of the tablets ranged from 0.152 g to 0.155 g. The tablets (F-1 
to F-9) comply with the uniformity of weight test.
 66, 67 
 
 
 
Table 7.14: Drug content, Uniformity of Weight and Friability of Sublingual tablets 
Formulations 
Drug content* 
(%w/w) 
Friability* (%w/w) Average Weight* (g) 
F-1 098.24±0.0 0.7096±0.032 0.153±0.0015 
F-2 095.20±0.0 0.9615±0.025 0.154±0.0053 
F-3 101.41±0.0 0.9897.±0.016 0.153±0.0026 
F-4 098.59±0.0 0.3123±0.027 0.152±0.0032 
F-5 101.90±0.0 0.3838±0.014 0.152±0.0021 
F-6 100.97±0.0 0.5727±0.035 0.153±0.0039 
F-7 102.48±0.0 0.5692±0.022 0.154±0.0044 
F-8 102.50±0.0 0.5832±0.011 0.155±0.0037 
F-9 101.68±0.0 0.7690±0.018 0.155±0.0018 
*Mean±SD (n=5) 
 
7.2.7. Disintegration Time 
The disintegration time of various formulations is given in Table 7.15. 
The disintegration time ranged from 08 seconds to11 seconds. All the 
formulations comply with the official standards.
 66 
7.2.8. Wetting Time 
The wetting time of various formulations is given in Table 7.15. 
The wetting time ranged from 03 to 05 seconds. 
27
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Table 7.15: Drug content, Uniformity of Weight and Friability of Sublingual tablets 
 
Formulations Disintegration Time* (Sec) Wetting Time* (Sec) 
F-1 09.00±0.0 04.00±0.032 
F-2 09.00±0.0 03.00±0.025 
F-3 08.00±0.0 03.00.±0.016 
F-4 11.00±0.0 05.00±0.027 
F-5 09.00±0.0 04.00±0.014 
F-6 09.00±0.0 04.00±0.035 
F-7 10.00±0.0 04.00±0.022 
F-8 09.00±0.0 03.00±0.011 
F-9 08.00±0.0 03.00±0.018 
*Mean±SD (n=5) 
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7.2.9. In vitro Dissolution study 27 
The results of in vitro dissolution study are shown in Table 7.16 to 7.19 
Table 7.16: In vitro dissolution study of the sublingual tablets containing varying 
concentrations of β - Cyclodextrin 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-1 F-2 F-3 
0 0 0 0 
05 84.24±0.64 86.40±0.38 87.12±0.49 
10 88.05±0.79 91.68±0.62 92.42±0.76 
15 91.90±1.15 94.84±0.59 94.89±1.09 
20 94.34±0.92 97.32±0.47 96.61±0.37 
30 98.24±0.88 99.08±0.76 99.04±0.89 
45 99.04±0.41 100.14±0.66 100.10±0.76 
60 101.76±0.36 101.2±0.54 101.20±0.42 
*Mean±SD (n=3) 
Figure 7.16: Percentage cumulative drug release of formulation F-1, F-2 and F-3 
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Table 7.17: In vitro dissolution study of the sublingual tablets containing varying 
concentrations of Chitosan lactate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-4 F-5 F-6 
0 0 0 0 
05 83.72±0.64 84.24±0.38 85.68±0.49 
10 88.32±0.79 87.33±0.62 88.07±0.76 
15 91.16±1.15 90.45±0.59 90.48±1.09 
20 93.59±0.92 93.60±0.47 92.90±0.37 
30 96.79±0.88 97.44±0.76 96.78±0.89 
45 98.52±0.41 99.25±0.66 98.53±0.76 
60 100.20±0.36 101.00±0.54 100.90±0.42 
*Mean±SD (n=3) 
Figure 7.17: Percentage cumulative drug release of formulation F-4, F-5 and F-6 
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Table 7.18: In vitro dissolution study of the sublingual tablets containing varying 
concentrations of Sodium lauryl sulphate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-7 F-8 F-9 
0 0 0 0 
05 84.96±0.64 85.68±0.38 86.40±0.49 
10 87.34±0.79 89.51±0.62 90.24±0.76 
15 90.74±1.15 91.93±0.59 92.67±1.09 
20 92.88±0.92 94.37±0.47 95.12±0.37 
30 96.76±0.88 96.11±0.76 96.86±0.89 
45 98.51±0.41 97.85±0.66 98.61±0.76 
60 99.55±0.36 99.60±0.54 100.30±0.42 
*Mean±SD (n=3) 
Figure 7.18: Percentage cumulative drug release of formulation F-7, F-8 and F-9 
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Figure 7.19: Percentage cumulative drug release of formulation F-1 to F-9 
 
All formulation showed maximum of 100% dissolution rate at the end of 60 
minutes. 
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7.2.10. In vitro Permeation study 26 
The results of in vitro permeation study in egg membrane are shown in Table7.20-7.23 
Table 7.20: In vitro permeation study in egg membrane of the sublingual tablets 
containing varying concentrations of β - Cyclodextrin 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-1 F-2 F-3 
0 0 0 0 
05 26.72±0.64 31.20±0.38 33.60±0.49 
10 30.71±0.79 36.94±0.62 37.96±0.76 
15 35.02±1.15 41.84±0.59 42.88±1.09 
20 38.58±0.92 48.76±0.47 46.31±0.37 
30 44.76±0.88 53.28±0.76 54.76±0.89 
45 50.92±0.41 59.63±0.66 60.67±0.76 
60 56.89±0.36 62.12±0.54 66.06±0.42 
*Mean±SD (n=3) 
Figure 7.20: Percentage cumulative drug release of formulation F-1, F-2 and F-3 
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Table 7.21: In vitro permeation study in egg membrane of the sublingual tablets 
containing varying concentrations of Chitosan lactate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-4 F-5 F-6 
0 0 0 0 
05 31.36±0.64 34.24±0.38 35.36±0.49 
10 35.34±0.79 37.15±0.62 40.24±0.76 
15 38.92±1.15 42.89±0.59 45.06±1.09 
20 42.58±0.92 47.20±0.47 51.90±0.37 
30 47.58±0.88 53.83±0.76 57.93±0.89 
45 53.96±0.41 60.52±0.66 65.03±0.76 
60 60.95±0.36 67.34±0.54 72.28±0.42 
*Mean±SD (n=3) 
Figure 7.21: Percentage cumulative drug release of formulation F-4, F-5 and F-6 
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Table 7.22: In vitro permeation study in egg membrane of the sublingual tablets 
containing varying concentrations of Sodium lauryl sulphate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-7 F-8 F-9 
0 0 0 0 
05 24.32±0.64 25.44±0.38 28.32±0.49 
10 28.44±0.79 27.83±0.62 32.38±0.76 
15 32.34±1.15 31.55±0.59 37.40±1.09 
20 37.28±0.92 36.31±0.47 41.00±0.37 
30 41.04±0.88 42.28±0.76 43.87±0.89 
45 45.19±0.41 49.35±0.66 52.87±0.76 
60 52.14±0.36 56.24±0.54 62.06±0.42 
*Mean±SD (n=3) 
Figure 7.22: Percentage cumulative drug release of formulation F-7, F-8 and F-9 
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Figure 7.23: Percentage cumulative drug release of formulation F-1 to F-9 
 
 
 Formulation F-1, F-2, and F-3 showed 56.89%, 62.12% and 66.06% drug 
release at the end of 60 minutes. The formulation F-4, F-5 and F-6 showed 60.95%, 67.34% 
and 72.28% drug release at the end of 60 minutes. Formulation F-7, F-8 and F-9 showed 
52.14%, 56.24% and 62.06% at the end of 60 minutes.  Among these, F-6 showed 72.28% at 
the end of 60 minutes with high permeability. 
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7.2.11. Ex vivo Permeation study 26 
The results of ex vivo permeation study in goat sublingual mucosa are in Table 7.24-7.27 
Table 7.24: Ex vivo permeation study in goat sublingual mucosa of the sublingual tablets 
containing varying concentrations of β - Cyclodextrin 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-1 F-2 F-3 
0 0 0 0 
05 27.52±0.64 32.64±0.38 37.60±0.49 
10 31.08±0.79 37.93±0.62 39.98±0.76 
15 35.84±1.15 43.98±0.59 44.95±1.09 
20 40.06±0.92 50.64±0.47 48.43±0.37 
30 46.13±0.88 55.19±0.76 57.24±0.89 
45 51.84±0.41 61.59±0.66 63.37±0.76 
60 57.99±0.36 64.28±0.54 68.34±0.42 
90 65.00±0.59 71.80±0.88 75.00±0.38 
120 71.60±0.47 78.35±0.41 83.01±0.62 
*Mean±SD (n=3) 
Figure 7.24: Percentage cumulative drug release of formulation F-1, F-2 and F-3
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Table 7.25: Ex vivo permeation study in goat sublingual mucosa of the sublingual tablets 
containing varying concentrations of Chitosan lactate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-4 F-5 F-6 
0 0 0 0 
05 33.12±0.64 35.68±0.38 36.48±0.49 
10 36.98±0.79 39.29±0.62 42.19±0.76 
15 40.61±1.15 45.37±0.59 45.12±1.09 
20 44.62±0.92 50.13±0.47 53.95±0.37 
30 49.51±0.88 55.64±0.76 60.18±0.89 
45 56.41±0.41 62.21±0.66 67.18±0.76 
60 62.98±0.36 69.07±0.54 74.79±0.42 
90 68.24±0.59 74.94±0.88 80.32±0.38 
120 75.36±0.47 81.96±0.41 86.42±0.62 
*Mean±SD (n=3) 
Figure 7.25: Percentage cumulative drug release of formulation F-4, F-5 and F-6
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Table 7.26: Ex vivo permeation study in goat sublingual mucosa of the sublingual tablets 
containing varying concentrations of Sodium lauryl sulphate 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-7 F-8 F-9 
0 0 0 0 
05 24.64±0.64 28.16±0.38 33.12±0.49 
10 29.41±0.79 30.46±0.62 37.62±0.76 
15 36.32±1.15 34.88±0.59 42.54±1.09 
20 38.00±0.92 38.76±0.47 46.60±0.37 
30 42.73±0.88 44.79±0.76 51.22±0.89 
45 48.68±0.41 55.96±0.66 56.88±0.76 
60 54.44±0.36 57.74±0.54 63.82±0.42 
90 60.63±0.59 64.64±0.88 70.21±0.38 
120 67.11±0.47 70.73±0.41 77.05±0.62 
*Mean±SD (n=3) 
Figure 7.26: Percentage cumulative drug release of formulation F-7, F-8 and F-9 
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Figure 7.27: Percentage cumulative drug release of formulation F-1 to F-9 
 
 
 Formulation F-1, F-2, and F-3 showed 71.60%, 78.35% and 83.01% drug 
release at the end of 120 minutes. The formulation F-4, F-5 and F-6 showed 75.36%, 81.96% 
and 86.42% drug release at the end of 120 minutes. Formulation F-7, F-8 and F-9 showed 
67.11%, 70.73% and 77.05% at the end of 120 minutes.  Among these F-6 showed 86.42% at 
the end of 120 minutes with high permeability. 
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Table 7.28: Comparative ex vivo permeation study in goat sublingual mucosa of F-1,  F-4 
and F-7 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-1 F-4 F-7 
0 0 0 0 
05 27.52±0.64 33.12±0.64 24.64±0.64 
10 31.08±0.79 36.98±0.79 29.41±0.79 
15 35.84±1.15 40.61±1.15 36.32±1.15 
20 40.06±0.92 44.62±0.92 38.00±0.92 
30 46.13±0.88 49.51±0.88 42.73±0.88 
45 51.84±0.41 56.41±0.41 48.68±0.41 
60 57.99±0.36 62.98±0.36 54.44±0.36 
90 65.00±0.59 68.24±0.59 60.63±0.59 
120 71.60±0.47 75.36±0.47 67.11±0.47 
*Mean±SD (n=3) 
Figure 7.28: Percentage cumulative drug release of formulation F-7, F-4 and F-7 
 
F-4 showed good permeability compared to F-1 and F-7. 
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Table 7.29: Comparative ex vivo permeation study in goat sublingual mucosa of F-2, F-5 
and F-8 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-3 F-6 F-9 
0 0 0 0 
05 32.64±0.38 35.68±0.38 28.16±0.38 
10 37.93±0.62 39.29±0.62 30.46±0.62 
15 43.98±0.59 45.37±0.59 34.88±0.59 
20 50.64±0.47 50.13±0.47 38.76±0.47 
30 55.19±0.76 55.64±0.76 44.79±0.76 
45 61.59±0.66 62.21±0.66 55.96±0.66 
60 64.28±0.54 69.07±0.54 57.74±0.54 
90 71.80±0.88 74.94±0.88 64.64±0.88 
120 78.35±0.41 81.96±0.41 70.73±0.41 
*Mean±SD (n=3) 
Figure 7.29: Comparative percentage cumulative drug release of F-2, F-5 and F-8 
 
F-5 showed good permeability compared to F-1, F-2, F-4, F-7 and F-8. 
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Table 7.30: Comparative ex vivo permeation study in goat sublingual mucosa of F-3, F-6 
and F-9 
Time (Mins) 
Cumulative Percentage Drug Release* 
F-3 F-6 F-9 
0 0 0 0 
05 37.60±0.49 36.48±0.49 33.12±0.49 
10 39.98±0.76 42.19±0.76 37.62±0.76 
15 44.95±1.09 45.12±1.09 42.54±1.09 
20 48.43±0.37 53.95±0.37 46.60±0.37 
30 57.24±0.89 60.18±0.89 51.22±0.89 
45 63.37±0.76 67.18±0.76 56.88±0.76 
60 68.34±0.42 74.79±0.42 63.82±0.42 
90 75.00±0.38 80.32±0.38 70.21±0.38 
120 83.01±0.62 86.42±0.62 77.05±0.62 
*Mean±SD (n=3) 
Figure 7.30: Comparative percentage cumulative drug release of F-3, F-6 and F-9 
 
F-5 showed good permeability compared to all other formualtions. 
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7.3. OPTIMIZED FORMULATION  
7.3.1. PREFORMULATION STUDIES  
Table 7.31: Preformulation Parameters of the Optimized Formulation F-6 
S.No Parameters F-6 
1.  Bulk density* (g/cm3) 0.500±0.047 
2.  Tapped density* (g/cm3) 0.5319±0.068 
3.  Compressibility index* (%) 05.99±0.059 
4.  Hausner’s ratio* 1.063±0.027 
5.  Angle of Repose* (θ) 29.17±0.028 
*Mean±SD (n=5) 
7.3.2. POST COMPRESSION STUDIES  
Table 7.32: Post-Compression Parameters of the Optimized Formulation F-6 
S.No Parameters F-6 
1.  Thickness* (mm) 3.2±0.0 
2.  Diameter* (mm) 8.0±0.0 
3.  Hardness* kg/cm
2
 4.3±0.2236 
4.  Drug content* (%w/w) 100.97±0.0 
5.  Friability* (%w/w) 0.5727±0.035 
6.  Average Weight* (g) 0.153±0.0039 
7.  Disintegration Time* (Seconds) 09.00±0.0 
8.  Wetting Time* (Seconds) 04.00±0.035 
*Mean±SD (n=3)
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8. SUMMARY AND CONCLUSION 
8.1. SUMMARY 
In this work an attempt was made to design sublingual drug delivery system 
containing an Antimigraine drug. The main objective of the present research work was to 
overcome the hepatic first pass metabolism, provide controlled release and to enhance the 
permeability. 
The conventional dosage forms available are associated with low bioavailability 
problems due to extensive first pass metabolism where in antimigraine agents are also 
characterized by highly soluble nature with low permeability, due to which frequency of 
dosing is increased, which results in patient incompliance. In order to overcome these 
drawbacks, drugs can be developed in form of sublingual drug delivery system. 
Sublingual drug delivery systems provide additional advantages over conventional tablets 
including termination of drug action in case of toxicity by removing the dosage form from 
the buccal cavity. 
The scheme of work has been divided into various parts. The collection of 
theoretical and technical data by extensive literature survey, review of literature and drug 
profile is presented in chapter 3 and 4 respectively. This was followed by procurement of 
materials and standardization of all materials used in the formulation of sublingual tablets. 
Sublingual tablets were prepared by direct compression method using Rizatriptan 
benzoate and different permeation enhancers like β-Cyclodextrin, Chitosan lactate and 
Sodium lauryl sulphate in different ratios and Crospovidone as superdisintegrant in order 
to release the drug in immediate manner. 
The tablets were evaluated for Disintegration time, Weight variation, Thickness, 
Hardness, Percentage friability, Wetting Time, Drug Content and In vitro dissolution 
studies, In vitro permeation study on egg membrane and Ex-vivo permeation study on goat 
sublingual mucosa. The resulting tablets were evaluated considering the disintegration 
time as well as permeation as the main criteria. Disintegration time of all batches was 
found to be between 08– 12 sec. Friability and hardness were also good in all batches. Ex-
vivo as well as In vitro permeation study of Batch F-6 was found to be high with good 
disintegration time, friability and hardness. Batch F-6 showed rapid dissolution rate and 
complete dissolution was achieved within 60 min. Formulation F-6 was considered as the 
best formulation. 
The results obtained have been discussed in chapter 7. Results of FT-IR 
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revealed that there was no chemical interaction between the drug and the permeation 
enhancers used. The prepared tablets showed good disintegration time. The release 
pattern of the formulations was good. 
Stability studies of the selected formulation was carried out to determine the 
effect of formulation additives on the stability of the drug and also to determine the 
physical stability of the formulation. The stability studies were carried out at 40 ºC/75% 
RH for 90 days. There was no significant change in the physical property and drug 
content during the study period. 
From the above the results, formulation F-6 was found to be the best 
formulation for the sublingual delivery of Rizatriptan benzoate that complied with all 
the parameters. However, in vivo experiments need to be carried out to know the 
absorption pattern and bioavailability of drug from the sublingual tablets and thus 
enabling us to establish           in vitro – in vivo correlation. 
 
8.2. CONCLUSIONS 
The concept of sublingual tablets containing Rizatriptan benzoate offers a suitable 
and practical approach in serving the desired objective of management of Migraine. Most 
of the excipients used in the formulation are water-soluble and hence have better patient 
acceptability. The present work of formulating a sublingual tablet containing Rizatriptan 
benzoate was successful in terms of reducing manufacturing difficulties, cost and 
providing better patient compliance with effective medication.  
It has been observed from the above study that excipients like Mannitol, 
Microcrystalline cellulose, Crospovidone, Aspartame, Chitosan lactate, Beta-Cyclodextrin 
and Sodium lauryl sulphate etc. were ideal excipients and effective for formulating 
sublingual tablets. Sublingual tablets provide several advantages especially when 
administered to children and elderly patients. Rapid absorption into the systemic 
circulation within short time period may be achieved. The batch F-6 was considered to be 
the best among all other batches since it exhibited good dissolution profile, disintegration 
time, uniformity of drug content and further good stability and ex- vivo as well as in-vitro 
permeation profile. The following parameters were obtained for optimized batch F-6 
 Disintegration time -09 seconds 
 In-vitro permeation study on egg membrane- 83.75% at the end of 120 minutes 
 Ex-vivo permeability study on goat sublingual mucosa- 86.42% at the end of 120 
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minutes 
From the overall results, it is clear that the formulation F-6 containing 3% of Chitosan 
lactate is the optimal formulation among the other formulations, as it produced better drug 
permeability than other formulations. 
 
8.3. SCOPE OF THE STUDY 
 The research work may be extended by using different permeation enhancers of 
natural or synthetic origin in various ratios for the formulation of sublingual 
tablets. 
 In vivo  studies  need  to  be  undertaken  to  establish  in-vitro  and  in-vivo 
correlation. 
 In vivo study using gamma scintillography method. 
 Pharmacokinetic and toxicity study. 
 Scale up studies for the optimized formulation. 
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